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ABOD: adriamycin, bleomycin, vincristin, dacarbazine 
BEP: Cisplatin, etoposide, bleomycin 
CACS: Coronary artery calcium score 
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CI, cardiac index 
CVD: cardiovascular disease 
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HLSs: Hodgkin’s lymphoma survivors 
hsCRP: high sensitivity CRP 
IVSd: interventricular septum thickness  
LA: left atrium diameter  
LVEDD: left ventricular end diastolic diameter 
LVEDV: left ventricular end diastolic volume 
LVESD: left ventricular end systolic diameter 
LV-FS: left ventricular shortening fraction 
LVPW, left ventricular posterior wall 
MDCT: multi-detector computed tomography scanner 
MOPP: nitrogen mustard, vincristine, procarbazine, prednisone 
MVPP: nitrogen mustard, vinblastine, procarbazine, prednisone 
NRH: Norwegian Radium Hospital 
PAS: pre-cranial atherosclerosis score 
Pro-BNP: pro-Brain Natriuretic Peptide  
PVB: cisplatin, vinblastin, bleomycin 
RPLND: retroperitoneal lymph node dissection 
sCD40L: soluble CD40 Ligand 
TC: Testicular cancer 
TCSs: Testicular cancer survivors 
vWF: von Willebrand factor
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1 INTRODUCTION 
 
1.1 Testicular cancer 
1.1.1 Epidemiology 
Testicular germ cell tumors (TC) accounted for about 2% of all new cases of cancer in 
Norway in 2007 and is the most common cancer in males below the age of 40 years.1 In 
Norway the incidence of TC has increased from 3 to 11 per 100 000 the last 50 years.2 
A similar increase in the incidence of testicular cancer is seen in most European 
countries.3 The 5 year relative survival rate registered in Norway in 1998 – 2002 was 
97%.1 As most cases of TC appear before the age of 40, the life expectancy of testicular 
survivors (TCSs) is 30 to 50 years if not curtailed by treatment-related sequelae. The 
consequence is that the prevalence of TCSs is increasing. In 2007 there were 5515 men 
with TC which represent about 3% of all males with a diagnosis of cancer.1  
 
Genetic and environmental factors probably starts their influence during early embryonic 
life and may cause TC through cryptorchidism (incomplete desence of one or both testis 
during embryological life), hypogonadism and infertility.3-5   
 
1.1.2 Histopathology and staging 
Approximately half of the patients are diagnosed with seminomas at a mean age of 37 
years. Seminomas are highly radio-sensitive and 80 % of the patients are diagnosed with 
non-metastatic disease.1, 6 The majority of primary germ cell tumors are homogenous 
cells with solely seminomal elements.7  
Non-seminoma accounts for the remaining 50% of TC and consists of several histological 
subgroups like choriocarcinoma, yolk sac tumor, teratoma.7 Most cases appear in the 
third decade.6 Approximately 50% of the patients have metastases at the time of 
diagnosis. Non-seminomas are relatively radio-resistant. Malignant germ cell tumors may 
produce human chorionic gonadotropin (HCG) and/or glycoprotein α-fetoprotein (AFP), 
tumormarkers which can be demonstrated in serum. Staging is performed according to 
the Royal Marsden Staging System (Table 1).8  
 
 10 
Table 1 The Royal Marsden Staging System.  
 
 
Stage  Description  
I  Tumor confined to the testicle. No evidence of metastases.  
IM No radiological evidence of metastases, but positive markers after orchiectomy 
II 
 
A  
B  
C  
Involvement of infra-diaphragmal lymphadenopathy.  
 
Maximum diameter of metastases < 2 cm  
Maximum diameter of metastases 2-5 cm  
Maximum diameter of metastases >5 cm  
III  Involvement of supradiaphragmatic lymphadenopathy.  
A, B and C as for stage II.  
IV  Hematological metastases. Involvement of lungs, liver, skeleton and/or brain.  
 
 
Except for the use of Royal Marsden Staging System, the International Germ Cell Cancer 
Collobarative Group (IGCCCG) has developed a prognostic classification for metastatic 
cases based on histology (i.e. seminoma or non-seminoma), extent and localization of 
metastases and the level of tumor markers.9  
 
 
1.1.3 Treatment of TC 
Treatment of TC patients starts with orchiectomy of the tumor bearing testicle. Post-
orchiectomy therapy depends on histology (seminoma vs non-seminoma) and the stage of 
the disease. As the present investigations are restricted to TC patients treated at the NRH 
from 1980-1994, Table 2 summarizes the standard treatment policies during these 15 
years. Most of the patients are included in international trials and the results are published 
elsewhere.9-32 
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Table 2 Post-orchiectomy policies for TC at NRH, 1980 – 1994. 
 Seminoma Non-seminoma 
Stage I Infradiaphragmatic para-aortic/pelvic 
or 
Para-aortic radiotherapy 20-30 Gy 
 
≤1988 RPLND with adjuvant 
chemotherapy in case of metastases 
(2-3 cycles) 
≥1989 Surveillance or adjuvant 
chemotherapy (2 cycles) 
Stage II 
(incl. stage 1M) 
Limited: Infradiaphragmatic radiotherapy (36 
Gy) with or without adjuvant chemotherapy 
(1 cycle) 
Extended: Chemotherapy (3-4 cycles) 
Limited: RPLND with adjuvant 
chemotherapy in case of metastases 
(2-3 cycles) 
Extended: 3-6 cycles chemotherapy 
followed by surgery and post-op. 
adjuvant chemotherapy if residual 
metastases are present 
Stage III-IV Chemotherapy (4 cycles) occasionally 
followed by post-chemotherapy surgery or 
radiotherapy ≤ 36 Gy 
As outlined for stage II 
(Extended) 
Post-chemotherapy 
relapse/progression 
Alternative chemotherapy + surgery / radiotherapy ≤ 45 Gy 
 
Radiotherapy: Only infra-diaphragmatic radiotherapy was provided as initial treatment, 
the upper border of the target field being the disk between the 10th and 11th thoracic 
vertebra. If more than 1/3 of the renal parenchyma was within the target field, lead 
shields were applied after 20 Gy, restricting the target dose to maximally 1/3 of the renal 
parenchyma. The field included the abdominal aorta and the apex of the heart. 
Chemotherapy: Up to 1985 PVB (cisplatin, vinblastin, bleomycin) was the standard 
chemotherapy for each cycle. Thereafter BEP (bleomycin, etoposide, cisplatin) 
chemotherapy was introduced as the standard chemotherapy. In different trials other 
combinations and various numbers of cycles were explored, using vincristine, carboplatin 
ifosfamide, in addition to cisplatin. Relapse treatment (after previous chemotherapy) 
could include limited doses of adriamycin or metotrexate along with ifosfamide. 
 
1.2 Hodgkin’s lymphoma 
1.2.1 Epidemiology 
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Hodgkin’s lymphoma (HL) accounts for only 0.4% of incident cancer in Norway in 2007, 
even though HL comprises about 15% of all lymphomas in western countries.1, 33 The 
age-adjusted incidence in 2003 – 2007 among men was 2.8 per 100 000 while it was 2.0 
per 100 000 in women which is in line with other European countries and the US. The 
incidence varies considerably between different age groups, demonstrating a bimodal 
shape (Figure 1). In 2007 114 men and women were diagnosed with HL.1 Most patients 
with HL are in their late teens or young adulthood. Thus, it accounts for about 15% of all 
cancer among young adults (15 – 24 years).33 The incidence of HL during the past 
decades has been remarkably stable, in contrast to the increased incidence of Non-
Hodgkin’s lymphoma.  
 
Figure 1 HL incidence according to age registered in 1997 - 2001. The Cancer Registry 
of Norway (blue line: males; red line: females) 
 
 
Due to modern radio- and chemotherapy there has been a marked increase in the survival 
rates over the last 50 years (Figure 2). Overall, the 5 year relative survival rate is 
approximately 90% according to the Cancer Registry of Norway.33  
 
The most frequently identified risk factors of HL are Epstein-Barr virus (EBV), human 
immunodeficiency virus (HIV), autoimmune disorders, allogeneic bone marrow 
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transplantation and multiple genetic factors.33 Interestingly, elevated IL-6 levels linked to 
genetic polymorphism of the IL-6 gene has been associated with increased risk of HL.34  
 
Figure 2 Five year relative survival rate. The Cancer Registry of Norway (blue line: 
males, red line: females). 
 
 
1.2.2 Histopathology and staging 
HL is divided in to major types called nodular lymphocyte predominant HL (NLPHL) 
and classical HL (CHL). Among the four subtypes of CHL, nodular sclerosis CHL 
(NSCHL) constitutes about 70% and affects primarily young adults from developed 
countries and involves mediastinum in 80% of cases.35 The origin of HL is B – 
lymphocytes which in most cases are not able to produce immunoglobulin, at least for 
CHL.36 Importantly, most lymph nodes or extra-nodal organs involved by HL contain 
relatively few neoplastic cells, but are dominated by reactive inflammatory cells.35, 37  
 
Basic evaluations performed in patients with HL include a detailed medical history with 
focus on pre-existing medical conditions, the presence of night sweats, fever, weight loss 
(B-symptoms) and a medical examination. In many cases the patient presents with a 
localized painless and firm mass lesion in the neck or supraclavicular fossa.38 Routine 
blood tests have included sedimentation rate, full blood counts, liver- and renal function 
tests including LDH and serological tests for relevant viral infections as they have 
become available over the last decades (Hepatitis B and C, HIV, EBV).39 
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Since the 1980ies, radiological evaluations have relied mostly on CT scans of the neck, 
thorax, abdomen and pelvis, supplemented with ultrasonography of abdomen. A bone 
marrow biopsy, performed uni- or bilaterally, has been mandatory except in some cases 
of stage IA disease on the neck. Lymphangiography has been part of the staging until the 
1990ies, but with the advent of better imaging modalites, it has later been omitted. 
Routine staging laparotomy was abandoned in Norway in 1980 and since that time it has 
only been used in isolated special cases.  Positron emission totmography (PET) alone or 
combined with CT (PET-CT) has not been used before year 2000..  
 
Staging is performed to decide which treatment to apply to HL patients and to predict 
prognosis. Over the last decades the Ann Arbor staging system with its different revisions 
and modifications has been used at the NRH (Table 3).40 Early stage disease has typically 
been defined as stage I and II and advanced stages as stages III and IV. In addition to the 
Ann Arbor staging system, other clinical, laboratory or radiological findings have been 
used to identify patients within the early stages at higher risk of treatment failure (such as 
presence of B-symptoms and/or bulky tumor, 4 or more involved regions, infra-
diaphragmatic disease, lymphocyte depleted subtype). Bulky disease is a large lymph 
node mass beyond 6-10 cm, depending on the definition of various investigators, or a 
mediastinal tumor greater than or equal to one third of the internal transverse diameter 
measured at level of the T5/6 intervertebral disc on chest radiography. Thus, since 1980, 
stage I and II disease has been subcategorized into a favorable group without risk factors 
and an intermediate group with risk factors. 
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Table 3 Cotswold Modification of the Ann Arbor Staging Classification40 
 
Stage I 
Stage IE 
Involvement of a single lymph node region OR  
Involvement of a single extralymphatic site 
Stage II 
 
Stage IIE 
Involvement of two or more lymph node regions on the same side of the 
diaphragm OR  
Localized contiguous involvement of only one extranodal organ or site 
and its regional lymph nodes with or without other lymph node regions on 
the same side of the diaphragm 
Stage III 
 
Stage IIIS 
Stage IIIE 
Stage IIISE 
Involvement of lymph node regions on both sides of the diaphragm  
POSSIBLY ACCOMPAINED BY 
Involvement of the spleen OR 
Localized contiguous involvement of only one extranodal organ site OR 
Both of the above 
Stage IV Disseminated (multifocal) involvement of one or more extranodal organs 
or tissues, with or without associated lymph node involvement or isolated 
extralymphatic organ involvement with distant (non – regional) nodal 
involvement 
Designations applicable to 
any stage 
 
A No symptoms 
B Fever (> 38 oC), night sweats, unexplained loss of > 10% body weight in 
previous 6 months  
X Bulky disease 
E Involvement of a single extranodal site that is contiguous or proximal to 
the known nodal site 
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1.2.3 Treatment of HL 
The treatment strategies for HL at the NRH have followed national and international 
guidelines, and are summarized in Table 4 for the period 1980-1988.41-44 Based on the 
staging the patients are divided into 3 groups; patients with stage I or II without or with 
risk factors and patients with stage III or IV disease.45 Disease and treatment 
characteristics for each patient were obtained from medical records, including type of 
radiotherapy (mantle field vs. mediastinal field only) and details regarding the use of 
additional chemotherapy.  
 
Table 4 Treatment of HL at NRH 1980-1988.46 
  
Chemotherapy 
 
 
Radiotherapy 
 
Dose and fractions of 
radiotherapy 
 
Stage I & II 
 
   
1980-88 With risk factors*:  
4 ABOD, ChlVPP or 
ABOD/ChlVPP 
(alternating) before 
radiotherapy 
Extended field radiotherapy 
(Mantle field /Inverted Y) 
2 Gy x 20,  
from 1982 1,8 Gy x 23 
 
Stage III & IV 
 
   
1980-1985 8 MVPP/ChlVPP To sites of initial bulky 
tumor or residual mass 
 
2 Gy x 20 
1985-1991 8 ChlVPP or  
8 ABOD/ChlVPP 
(alternating) 
To sites of initial bulky 
tumor or residual mass 
2 Gy x 20 or 
1,8 Gy x 23 
 
* Risk factors are presence of B-symptoms and/or bulky tumor, 4 or more involved regions, infra-
diaphragmatic disease, lymphocyte depleted subtype 
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Table 5 Summary treatment of TCSs and HLSs 
Treatment TCSs HLSs 
Radiotherapy 
- Dose (Gy) 
- Localization 
 
30 (30 – 45) 
Infra-diaphragmatic 
 
40 (27 – 44) 
Mantle or mediastinal field 
Chemotherapy Cisplatin 
Bleomycin, Vinblastin 
Etoposid 
Doxorubicin,  epirubicin 
Bleomycin, Vinblastin 
chlorambucil, procarbazine, 
prednisone 
 
 
 
1.3 Risk factors of cardiovascular disease (CVD) and second cancer in TCSs and 
HLSs 
1.3.1 CVD and second cancer in TCSs and HLSs 
TCSs are at an increased risk of CVD.47-51 There has been observed nearly a 2 fold 
increased risk of CVD median 10 years after treatment in patients treated with either 
radiotherapy alone, chemotherapy alone or both as compared to only surveillance or the 
general population.48, 52 Furthermore, even with the introduction of cisplatin and the 
reduction in the use of radiotherapy, the risk of non-germ cell cancer in TCSs remains 
high.53, 54 The cumulative risk of a second cancer in patients diagnosed with seminoma or 
nonseminoma 40 years after treatment was 36% and 31% respectively compared with 
23% in age matched controls.54 Cancers located below the diaphragm like colon cancer, 
bladder cancer, pancreatic cancer and stomach cancer are frequently observed in TCSs, 
but there is also observed a higher risk of lung cancer and leukaemia compared to the 
general population. 
 
The mortality due to HL reaches a plateau 10 years after the treatment.55 Unfortunately, 
mortality due to especially CVD and a second cancer continues to rise with increasing 
follow-up time (Figure 3). Several reports indicate that CVD appears about 10 years after 
treatment, including coronary artery disease (CAD), congestive heart failure due to 
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cardiomyopathy, valvular disease, and constrictive pericarditis.56-63 In 1080 HLSs treated 
in 1969 – 1997 the relative risk of cardiac death was 2.8 15 – 20 years after treatment, 
and this risk increased to 4.5 for a group observed more than 20 years after treatment.64 
There is also increased risk of Non-Hodgkin’s lymphoma but the majority of 
malignancies are solid tumors, especially breast, lung and gastrointestinal cancer.65-68 
Among 32591 HLSs the observed to expected ratio for a second malignancy was 2.3 
(95% CI 2.2 – 2.4), and almost 1/3 had been followed for more than 25 years.65 
 
Figure 3 The actuarial risk for major disease categories in HL.55 
 
 
1.3.2 Radiotherapy and CVD 
Mechanisms 
The acute effects of radiotherapy are supposed to cause small vessel thrombosis due to 
endothelial cell swelling and endothelial inflammation .69 The irradiated endothelium is 
characterized by activation of NF-αB, alterations in the expression of adhesion 
molecules, chemotactic cytokine production and leukocyte infiltration into tissues.70 This 
response is sustained for several weeks. Radiotherapy is also believed to cause fibrosis 
and endothelial damage through generation of reactive oxygen species.71 A study was 
performed on cervical arteries after neck dissection in 17 patients previously irradiated 
for malignant neck tumor.72 The tissue was harvested 4-6 weeks after radiotherapy. The 
irradiated cervical arteries as compared to contra-lateral non-irradiated vessels did not 
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express eNOS and had impaired vasodilatation upon acetylcholine stimulation. Another 
study in patients treated with mediastinal radiotherapy for breast cancer demonstrated 
decreased endothelium-dependent vasodilatation with the use of acetylcholine in the 
irradiated axillary arteries compared to the non-irradiated arteries in the same patients.73 
An in vitro study has shown that the endothelial marker vWF is released from isolated 
vessels early after irradiation. Radiotherapy may thus lead to endothelial dysfunction as 
demonstrated by reduced flow-mediated dilatation and increased intima-media 
thickness.74, 75 These adverse effects of radiotherapy may initiate or accelerate 
atherosclerosis directly or through interference by established cardiovascular risk factors 
like hypercholesterolemia, hypertension and the metabolic syndrome which are 
frequently observed among TCSs.76, 77 A self-perpetuating process of endothelial 
inflammation may be the results of these stimuli. Eventually, these processes are also 
believed to be responsible for the damage of coronary arterioles and capillaries, and may 
lead to myocarditis, pericarditis and coronary ischemia.78 In summary, the observed 
increase in CVD among TCSs and HLSs may be due to a direct and localized effect of 
radiotherapy and/or an indirect effect mediated by the activation of the immune system 
associated with the increase in the inflammatory markers. The more frequent occurrence 
of CVD in HLSs compared to TCSs most likely represent both a dose-effect relationship 
and a direct toxic effect on the heart caused by mediastinal radiotherapy. TC patients 
received about 30 Gy of infra-diaphragmatic radiotherapy while HL patients received 
about 40 Gy of mediastinal radiotherapy. 
 
CVD associated with radiotherapy 
An increased cardiovascular mortality in TCSs has been reported by Zagars who studied 
453 patients with seminoma stage I or II treated with infra-diaphragmatic radiotherapy 
after orchiectomy.51 Seventy-one (16%) patients had received additional mediastinal 
radiotherapy. In those with an observation time exceeding 15 years the cardiac 
standardized mortality ratio (SMR) was higher among those who had received infra-
diaphragmatic radiotherapy (SMR = 1.75) and those who received additional mediastinal 
radiotherapy (SMR = 2.33) compared to the general population (US males). In contrast, 
van den Belt-Dusebout et al did not observe any increased risk of cardiovascular events 
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in TCSs treated with infra-diaphragmatic radiotherapy alone while mediastinal 
radiotherapy was followed by a nearly four fold risk of a composite end point of 
myocardial infarction, angina pectoris and heart failure..50 Fosså et al showed that TCSs 
younger than 35 years and treated with surgery combined with radiotherapy had a 
standardized mortality ratio of 1.70 for all CVD compared to the general population.52  
 
The main cause of cardiovascular disease in HLSs is related to the treatment with 
mediastinal radiotherapy. Cardiac mortality has been shown to be significantly increased 
at doses beyond 30 Gy.79 Aleman et al observed also a 3.6-fold increased risk of 
myocardial infarction and a 4.9-fold increased risk of cardiac heart failure in 1474 HLSs 
with a follow-up of 18.7 years as compared to the general population.57 Mediastinal 
radiotherapy increased the risks of MI, angina pectoris, CHF, and valvular disorders by 2- 
to 7-fold. The risk for MI became significant at 10 years after treatment and remained 
elevated up to 25 years after treatment. There has been observed a relative risk of death 
from myocardial infarction at 2.5 in 7033 HLSs with a median follow-up of 9.9 years 
compared to the general population.63 The risk of death and myocardial infarction was 
elevated from the first year after treatment and remained elevated up to 25 years after 
treatment. Mantle field radiotherapy without chemotherapy was associated with increased 
risk of death due to myocardial infarction (relative risk 3.2 (2.3 – 4.3)). CAD is 
frequently observed even in asymptomatic HLSs.59 Stress echocardiography and 
radionuclide perfusion imaging were performed in 294 patients treated with mediastinal 
radiotherapy who had no symptoms of heart disease. Based on the results from the 
imaging 40 patients underwent angiography and 22 patients had coronary stenosis of ≥ 
50%. Furthermore, radiotherapy is known as a cause of restrictive cardiomyopathy.56 
 
The cardiac valves are included in the mediastinal radiotherapy field, and it has been 
shown that the incidence of valvular dysfunction increased during the second decade after 
treatment with mediastinal radiotherapy for HL.56, 58, 61 After 20 years, 6 – 15% of HLS 
have moderate or severe valvular regurgitation in the aortic or mitral valve. The actual 
risk of valvular dysfunction in patients treated for HL is under debate. Aleman et al. 
observed a hazard ratio of 7.0 and a cumulative incidence of approximately 10% for 
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having clinically diagnosed valvular disorder after a median observation time of 13 years 
in HLSs treated with mediastinal radiotherapy.57 Hull et al. reported that 6% of 415 HLSs 
had clinically important valvular disorder 20 years after radiotherapy.61 Heidenreich 
performed a cross-sectional follow-up investigation in 73 patients 20 years after 
radiotherapy. Twelve (16%) had aortic stenosis, 11 (15%) had moderate or severe aortic 
regurgitation, and 3 (4 %) had mitral regurgitation.58 However, the cause of the enhanced 
susceptibility of valvular dysfunction in some of the HLSs is unknown. 
 
In patients treated with mantle field radiotherapy the pre-cranial arteries are exposed to 
irradiation. Accordingly, an increased risk of carotid artery stenoses and stroke have been 
reported in HLSs.61, 80-82 Radiotherapy was associated with a subsequent stroke in 24 of 
1926 HLSs compared to 9 of 3846 healthy siblings after a follow-up of 17.5 years (RR = 
5.6). A Dutch group reported a relative risk of stroke and transient ischemic attack at 2.2 
(95% CI 1.7 – 2.8) and 3.1 (95% CI 2.2 – 4.2) respectively in 2201 HLSs after a median 
follow-up of 17.5 years.82 The cumulative incidence of stroke or transitory ischemic 
attack (TIA) 30 years after the treatment was 7%. Cardio-embolism and large-artery 
atherosclerosis were the sources of an event in 24% and 36% of the patients respectively. 
Hull et al observed an actuarial incidence of stroke, TIA, carotid artery stenosis and 
subclavian stenosis at 3 % at 10 years and 7 % at 20 years.61 However, it was suggested 
from that study that patients who developed TIA or stroke did so because radiotherapy 
accelerated the atherosclerotic process in these patients who were already 51 years old at 
the time of radiotherapy and who experienced an event within 6 years after treatment. 
The same study showed that 30 of 404 (7.4 %) had carotid or subclavian disease after a 
median of 11.2 years after radiotherapy.61 Younger patients who were on average 20 
years when treated with radiotherapy demonstrated isolated carotid or subclavian stenosis 
after a median follow-up of 21 years.  
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1.3.3 Chemotherapy and CVD 
Mechanisms 
Chemotherapy with the use of either cisplatin or anthracyclines has become the corner 
stone in the treatment of TC and HL respectively. These agents mediate their anti-cancer 
effects by different mechanisms and have different long-term adverse effects.  
 
Cisplatin-based chemotherapy used in the treatment of TC induces apoptosis through 
its cross-linking action on DNA.83 There is evidence of cisplatin in plasma even 20 years 
after treatment which may partially explain the long-term toxic effects of cisplatin.84 In 
vitro studies of the endothelial function after administration of cisplatin and bleomycin 
have clearly demonstrated endothelial dysfunction, inflammatory activation by increased 
levels of IL-1, IL-6, TGF-beta and inhibited proliferation of endothelial cells.85, 86 
Furthermore, TC patients treated with chemotherapy have reduced flow-mediated 
dilatation and increased intima-media thickness.87, 88 Thus, chemotherapy may cause 
CVD through endothelial dysfunction and inflammation. 
 
Anthracyclines applied to HL patients, may induce cardiomyopathy and aggravate 
cardiac disorders by various mechanisms.89-92 The most important mechanism is 
considered to be the transfer of single electrons from the electron transport chain in 
mitochondria to doxorubicin giving rise to oxygen radicals.93 But also the release of 
cytochrome c from the mitochondria and the subsequent apoptosis and transcriptional 
changes in intracellular ATP production in cardiac myocytes may play an important 
role.92 Left ventricular shortening fraction (LV-FS) related to impaired contractility and 
reduction in ventricular mass and wall thickness has been observed 12 years after 
treatment with anthracyclines for childhood acute lymphoblastic leukemia.94 
 
Cardiovascular disease associated with chemotherapy 
Meinardi demonstrated an observed-to-expected ratio of 7.1 (95% CI 1.9 – 18.9) for 
CVD in 87 TCSs treated with cisplatin-based chemotherapy 10 years after the treatment 
as compared to the general population.49 Even though this was the first study to compare 
CVD events in TCSs to the general population, the study is of limited value. The sample 
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size was small with only 5 events in the 87 patients. van den Belt-Dusebout demonstrated 
a 2 fold increased risk after treatment with chemotherapy (BVP-regimen) compared to 
patients treated with only surgery.50 Fosså et al showed that men treated with 
chemotherapy had higher mortality from CVD median 10 years after treatment with a 
standardized mortality ratio of 1.58 compared to the general population.52 
 
Chemotherapy may also directly influence cardiovascular disease in HLSs.63, 95 The risk 
of anthracycline induced heart failure was estimated to 4-5% 15 – 20 years after 
treatment.96, 97 In HLSs the risk of heart failure is relatively low if the cumulative dose of 
doxorubicin is less than 300 mg/m2.89, 95 Aleman reported that the addition of 
anthracyclines to mediastinal radiotherapy gave a 3-fold increase in the risk of cardiac 
heart failure and a 2-fold increase in the risk of valvular disorders compared to 
mediastinal radiotherapy alone.57 
 
1.3.4 Treatment-related second cancer 
In TCSs the risk is of having a non-germ cell cancer is elevated in patients treated with 
radiotherapy alone or chemotherapy alone.98 Etoposide is a risk factor of acute 
myelogenic leukaemia.99  HLSs have an elevated risk of developing second 
malignancies.55, 60, 65, 100 In the first decade after treatment the appearance of leukemia 
probably due to alkylating chemotherapy is a feared malignancy.64 Recently it was shown 
that HLSs had approximately 30-fold increased risk of malignant mesothelioma due to 
radiotherapy.101 The risk of second malignancy is probably due to both radiotherapy and 
chemotherapy, although there is evidence that while the combined treatment with 
radiotherapy and chemotherapy gives an additive increase in the risk of lung cancer, the 
risk of post-HL breast cancer is reduced following chemotherapy.66-68 The explanation for 
the latter is probably that the decreased ovarian function caused by alkylating agents 
abort the hormonal stimulation that may be of importance in mediating radiation induced 
breast cancer. 
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1.3.5 Traditional risk factors 
Atherosclerosis is a multi-factorial disease involving oxidized LDL, HDL, inflammation, 
endothelial dysfunction and platelet activation and aggravated by traditional risk factors 
like hypertension, diabetes, hyperlipidemia and smoking.102 Hypertension, 
hypercholesterolemia and the metabolic syndrome are frequently observed among TCSs 
treated with cisplatin which may contribute to the increased risk of CVD.76, 77 A study by 
Sagstuen et al revealed that TCSs treated with cisplatin-based chemotherapy had higher 
levels of blood pressure, a higher prevalence of hypertension and a excessive weight gain 
compared with controls.76  Hypercholesterolemia (79%) and hypertension.(39%) were 
observed among 62 patients treated with chemotherapy for metastatic TC, 49 There is 
evidence that not only TC treated with chemotherapy but also patients treated with 
orchiectomy only are at increased risk of the metabolic syndrome.77  
 
Traditional risk factors are also of importance in HLSs. Hypercholesterolemia, 
hypertension, diabetes mellitus and smoking have been identified as risk factors of 
coronary and non-coronary disease in HLSs.57, 61, 81 Potentially, a high cholesterol may 
aggravate the adverse atherosclerotic processes associated with radiotherapy or 
chemotherapy in both TC and HL patients.  
 
1.3.6 Hypogonadism 
Impaired spermatogenesis is associated with TC. The treatment with bleomycin, cisplatin 
and radiotherapy is associated with hypogonadism.103-106 Hypogonadism is observed 
among TCSs and has been demonstrated in every fifth patient with TC before the start of 
treatment.107, 108 Likewise, it has been suggested that post-treatment gonadal dysfunction 
may be associated with pre-treatment reduced fertility in HLSs.109, 110 Alkylating agents 
and high-dose chemotherapy in male HLSs have been associated with hypogonadism.111 
Hypogonadism and low testosterone are associated with endothelial dysfunction, the 
metabolic syndrome, inflammation and CVD.112, 113  
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1.3.7 Inflammatory markers 
Indices of inflammation (e.g., high-sensitivity-C-reactive protein [hsCRP]), platelet-
mediated inflammation (e.g., soluble CD40 ligand [sCD40L]), and of endothelial cell 
activation (e.g., von Willebrand factor [vWF]) have all been shown to predict 
cardiovascular events.114-116 Chronic subclinical inflammation may be associated with 
cancer as a consequence of invasive tumor growth and secondary activation of the 
immune system. Furthermore, inflammatory markers like CRP, vWF and sCD40L may 
be associated with future cancer and a pre-cancerous condition.117-119 
 
C-reactive protein (CRP) is an acute phase protein produced by the liver in response to 
inflammatory stimuli.120 Infections, surgery and advanced cancer cause marked 
elevations of CRP. Chronic minor elevation in CRP identifies subclinical inflammation 
which has been suggested to be instrumental in driving atherosclerosis, but this 
hypothesis remains undefined.120 CRP is established as a predictor of cardiovascular 
events in patients with known CVD as well as in asymptomatic individuals with risk 
factors for CVD.121, 122    It has been shown that CRP is associated with advanced HL, the 
presence of B symptoms and subsequent relapse of the disease.123 However, there is 
evidence suggesting that CRP is not merely a marker of a manifest cancer but is also able 
to predict first-onset cancer. 124-127 Recently, CRP levels above 3 mg/l were identified as a 
marker of incident lung cancer in the general population in comparison to individuals 
with CRP < 1 mg/L.124 Although elevated levels of CRP have been associated with future 
colorectal cancer, Rifai et al were not able to demonstrate that increasing quartiles of 
CRP were associated with future cancer among more than 28000 women older than 45 
years, however the observation time was relatively short (58 months).128 
 
CD40 ligand is expressed on T-lymphocytes, monocytes and activated platelets while 
CD40 is expressed on the endothelium.115, 129, 130 It amplifies the endothelial cell response 
to inflammation partly by upregulating various CAMs (cellular adhesion molecules) and 
contribute to the regulation of hemostasis. This will lead to an increased transfer of LDL 
through the endothelium. An increased expression of CD40/CD40L has been seen in 
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patients with hypercholesterolemia.130 Elevated serum concentrations of CD40L in 
apparently healthy women predicted cardiovascular events.115 
 
Platelets are attached to the vessel wall through the binding of von Willebrand factor 
(vWF), which is localized beneath the endothelium and exposed in the case of endothelial 
injury.118 The Monica study revealed that vWf measured on populations in different 
European countries was significantly associated with number of cardiovascular events.131  
 
An association between sCD40L or vWF and cancer has also been suggested.132, 133 There 
is a lack of studies on the use of these markers as prognostic indicators.  
 
The evidence regarding inflammatory markers are mainly related to TCSs. Inflammatory 
markers and endothelial function were measured before and within 10 weeks after 
cisplatin-based chemotherapy in 65 TC patients with stage I to IV disease.87 There was an 
increase in the levels of vWF and carotid intima-media thickness compared to pre-
treatment values. Another study revealed increased levels of CRP, vWF, fibrinogen, 
plasminogen activator inhibitor (PAI-I) and tissue-type plasminogen activator (tPA) in 90 
patients treated with chemotherapy 7 years earlier compared to 47 healthy men.134 A third 
study by Vaughn et al compared 24 patients who had received cisplatin with 15 
chemotherapy naive patients.88 Chemotherapy decreased flow-mediated dilatation in the 
brachial artery and increased the level of soluble intercellular adhesion molecules in 
patients treated more than 2 years ago. 
 
1.4 Preliminary conclusion and aims 
Radiotherapy and chemotherapy may cause CVD and a second cancer through various 
mechanisms. The adverse effect of radiotherapy is probably dependent on both the 
localization and size of the radiation field, the total dose applied and indirect effects 
caused by a general inflammatory activity. The adverse effects of chemotherapy may be 
related to the mode of action of the used chemotherapeutic agent and their metabolism. 
Furthermore, the treatment with radio- and chemotherapy may have additive effects on 
the incidence of CVD and second cancer.  
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In order to reveal some insight in these mechanisms we investigated the presence of 
inflammation, lipid-related markers, blood pressure and hypogonadism in TCSs and if 
some of these markers (and especially CRP) may serve as predictors of future CVD and 
second cancer. In HL we focused on the development of valvular and myocardial 
dysfunction, the presence of coronary artery disease and atherosclerosis and focused on 
whether there were important predictors of cardiovascular adverse effects of mediastinal 
radiotherapy. We were able to perform studies on TCS and HL with an observation time 
exceeding 20 years for most of the participants.  
 
The aim of each separate paper: 
- Assess treatment-related differences in cardiovascular risk factors and 
inflammatory markers in testicular cancer survivors 11 years after treatment 
(Paper I). 
- Explore if high sensitivity (hs) CRP predict subsequent cardiovascular events or 
non-germ cell cancer in testicular cancer survivors (Paper II). 
- Evaluate the evolution and development of valvular and myocardial dysfunction 
in Hodgkin’s lymphoma survivors treated with mediastinal dysfunction (Paper 
III). 
- Assess the relation between premature coronary artery disease and coronary artery 
calcium score in Hodgkin’s lymphoma survivors (Paper IV). 
- Examine the interaction between radiotherapy and traditional risk factors on 
premature atherosclerosis in Hodgkin’s lymphoma survivors (Paper V). 
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2 SUBJECTS AND METHODS 
 
2.1 Study populations and design  
TCSs (Paper I and II) 
All surviving and disease-free men treated for unilateral TC in Norway during the period 
1980-1994 were invited to participate in a national survey conducted from 1998 to 2001 
(n = 1814). Patients with extragonadal germ cell tumors, bilateral TC, secondary 
malignancy except skin tumors and mental retardation were excluded. Patients treated for 
unilateral TC received a 219-item questionnaire and attended the outpatient department 
of the regional oncological unit for a clinical examination and blood testing.104 At the 
time of assessment; all men were free of any apparent infections or any other incidental 
disease. Furthermore, in some patients audiometry, spirometry and semen analysis were 
assessed. Institutional and regional ethical committees approved of this study, and all 
participants gave their written consent. 
 
Paper I and II are restricted to patients seen at the Norwegian Radium Hospital (NRH; 
968 of 1814 patients). Of these 968 patients, 727 (75%) men participated while 241 men 
declined or failed to show up for their scheduled outpatient visits (Figure 4). Eighty-eight 
men were excluded from our analyses because they were over 60 years of age at the time 
of the first follow-up and 50 were excluded because they were treated with both radio- 
and chemotherapy. Thus, a total of 589 men participated in the first follow-up (FU-1) 
presented in Paper I. The responders and the non-responders who were potentially 
eligible for the study were comparable in age at diagnosis and FU-1 and also with respect 
to the distribution of the histological diagnoses. The non-responders had a longer 
observation time (median 3 years older) than the responders. A later quality check 
revealed that 22 of the 50 patients believed to have received both radio- and 
chemotherapy actually had been treated with only chemotherapy. 
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Figure 4 Study population Paper I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invited TCSs 
968 
Age > 60 years 
21 
Non-responders in FU-1 
(No blood sampling) 
241 (25%) 
Observation time1: 14 (6-20) 
Age at follow-up:   43 (26-60) 
Surgery:        42 (21%) 
Radiotherapy:        73 (37%) 
Chemotherapy:       83 (42%) 
Responders in FU-1  
(With blood sampling) 
727 (75%) 
Observation time1: 11 (5-21) 
Age at follow-up:   42 (23-60) 
Surgery:       140 (24%) 
Radiotherapy:        231 (39%) 
Chemotherapy:       218 (37%) 
Both radio – 
and 
chemotherapy 
at FU-1 
13 patients 
Included in Paper I  
589 patients (92%) 
Observation time and age at follow-up are presented as median (range). Other values are number (%). 
  1 p:<0.01, all other comparisons p:>0.05.2 No returned questionnaire 
Age > 60 years 
88 
Non-responders < 60 years in FU-1 
(No blood sampling) 
220 (91%) 
Responders < 60 years in FU-1  
(With blood sampling) 
639 (88%) 
Both radio – 
and 
chemotherapy 
at FU-1 
50 patients 
Non-responders  
198 (90%) 
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Figure 5 Study population Paper II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation time and age at follow-up are presented as median (range). Other values are number (%). 
  1 p:<0.01, all other comparisons p:>0.05.2 No returned questionnaire
Responders in FU-1 
639 patients 
Responders in FU-2 
430 (76%) 
Non-responders in FU-22 
137 (24%)  
Observation time1: 18 (13-28) 
Age at follow-up1: 47 (32-67) 
Surgery:       26 (19%) 
Radiotherapy:       48 (35%) 
Chemotherapy:      59(43%) 
Radio- and Chemotherapy: 4 (3%) 
Observation time1: 20 (13-28) 
Age at follow-up1: 51 (31-69) 
Surgery:        105 (24%) 
Radiotherapy:        152 (35%) 
Chemotherapy:       158 (37%) 
Radio- and Chemotherapy: 15 (4%) 
Deaths after FU-1: 19 (3%) 
- CVD: 4  
- Cancer: 10  
- Other: 5  
Observation time: 11 (4-21) 
Age at follow-up: 42 (23-60) 
Surgery:       132 (23%) 
Radiotherapy:       211 (36%) 
Chemotherapy:     221 (38%) 
Radio- and Chemotherapy: 22 (4%) 
Included in Paper II 
CRP at FU-1 ≤ 10 mg/L 
586 (68%) 
Invited to FU-2 
567 patients (97%) 
53 patients excluded due to 
missing (n =36) or CRP > 
10 mg/L (n = 17)  
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 A second follow-up questionnaire-based survey (FU-2) was performed in 2007-2008 
median 8 (range 6 – 9) years after FU-1. Surviving TCSs were asked to have a clinical 
examination and blood sampling at their family doctor’s office. The blood samples were 
immediately mailed to the NRH where all biochemical analyses were performed. Of the 
567 remaining patients who were invited to FU-2, 430 (76%) returned the questionnaire 
(Figure 5). At the time of FU-2, 19 men had died; 4 had died from CVD and 10 from 
cancer.  
 
In Paper II all patients who participated in FU-1 were considered for inclusion as they 
were aged ≤ 60 years at FU-1, had no known second cancer and no apparent acute or 
chronic infections at blood sampling (FU-1). A criterion for inclusion was a valid CRP at 
FU-1. Thus, 36 patients in whom CRP was missing due to logistic reasons were 
excluded. In order to be certain of excluding all patients who may have an underlying 
infection, men with CRP > 10 mg/L (n = 17) were excluded. After the exclusion of 53 
men, 586 patients were included in the study and were eligible for analyses of a second 
cancer or a cardiovascular event (myocardial infarction, stroke, revascularization, and 
hospitalization for heart failure) after FU-1. A total of 15 patients who in the 
questionnaire reported a cardiovascular event prior to FU-1 were excluded. Thus, 571 
patients were eligible for the analysis of post-FU-1 cardiovascular events.  
 
HLSs (Paper III – V) 
Paper III is a longitudinal study assessing the development and evolution of valvular and 
myocardial dysfunction related to treatment with mediastinal radiotherapy and 
anthracyclines in HLSs. Between 1980 and 1988 427 patients were treated for HL at the 
NRH. In 1993 our group invited HLSs to perform echocardiography (FU-1) if they 
fulfilled the following criteria; mediastinal radiotherapy (with or without chemotherapy), 
age < 50 years at diagnosis and relapse-free survival for > 5 years (Figure 6).62 The 
median observation time at FU-1 was 10 years. All of the 32 surviving patients with 
moderate and severe regurgitations at FU-1 were in 2005 invited to participate in a 
second echocardiographic examination (FU-2). From the group of 80 patients without or 
with only mild valvular regurgitation we invited 25 age- and gender-matched survivors 
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for comparison. Six patients declined. Of the 51 remaining participants who were 
included in Paper III, 28 had at least one valve with moderate or severe regurgitation at 
FU-1. Four patients had either moderate pulmonal (n = 2) or tricuspid (n = 2) 
regurgitation but no or only mild aortic or mitral regurgitation. Thus, 24 patients had 
moderate mitral and/or aortic regurgitation. The remaining 27 patients demonstrated no 
(n =14) aortic or mitral regurgitation or only mild (n =13) aortic and/or mitral 
regurgitation. Prior to the re-examination at FU-2 three patients had received mechanical 
valve replacement (for aortic regurgitation, aortic stenosis and mitral regurgitation 
respectively), and for these patients the last preoperative echocardiography was included 
in FU-2 as the second follow-up examination. A cardiovascular event was in Paper III-V 
defined as myocardial infarction, percutaneous coronary intervention or coronary artery 
bypass graft surgery, valvular surgery, stroke or TIA.  
 
In Paper IV the cross sectional study aimed to quantify coronary artery calcium in HLSs 
and relate it to the presence and absence of CAD. All patients who were included in 
paper III were eligible for the study of coronary calcification. In order to be included for 
the analysis of coronary calcifications the participants needed a valid CT examination of 
the heart. Four patients were excluded; one had undergone a CT angiography of the neck 
vessels, but unfortunately no CT examination of the heart had been performed while three 
patients did not attend the CT examination. Two of the three patients who did not attend 
the CT examination had already received a mechanical valve and one was living abroad. 
In total, 47 patients with a valid CT examination of the heart with the estimation of 
coronary artery calcium score (CACS) were included. 
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Figure 6 Study populations in Paper III, IV and V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invited to FU-1 
129 patients 
Non-responders 
13 patients 
Eligible in FU-1 
116 patients 
No or only mild regurgitation in FU-1 
80 (69%) patients 
Moderate or severe regurgitation in FU-1 
36 (31%) patients 
Included in Paper III  
28 patients 
- Left sided regurgitation: 24 
- Right sided regurgitation: 4 
1 death due to CVD  
3 deaths due to cancer  
Included in Paper III and IV 
23 patients 
Invited to FU-2 
32 patients 
4 declined 
Age- and gender matched controls invited 
to FU-2; 25 patients 
2 declined 
1 with no CT 
angiography 
4 with mediastinal 
field only 
Included in Paper V  
18 patients 
3 with no CT 
examination 
Included in Paper V  
25 patients 
Included in Paper IV  
24 patients 
1 with no cardiac 
CT  examination 
Treated 1980 -88 
427 patients 
Deaths, < 5 years relapse free interval, no 
mediastinal field, > 50 years at diagnosis 
298 patients 
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Paper V is based on longitudinal assessments. The aim was to examine whether 
traditional risk factors and inflammatory markers could predict atherosclerosis and the 
presence of peripheral endothelial dysfunction in HLSs. Furthermore, we examined if 
atherosclerosis in the irradiated arteries was associated with peripheral endothelial 
dysfunction and markers of inflammation. A criterion for inclusion was that all patients 
had received radiotherapy against the neck vessels. Thus, 43 of the 51 patients included 
in Paper III and who had been treated with mantle field radiotherapy were eligible for the 
study of extra-coronary atherosclerosis as assessed by the CT angiography of the 
mediastinum and neck vessels.   
 
The Health Study of Nord-Trøndelag 
For comparison of lipid-related markers and the frequency of the metabolic syndrome, 15 
individuals from the second Health Study of Nord-Trøndelag County, Norway (HUNT-2) 
were randomly selected for each patient included in this study, matched for age and 
gender.135  The HUNT study consists of 3 surveys and is a longitudinal population-based 
epidemiological study in Nord-Trøndelag for the assessment and development of somatic 
and psychological issues. The compliance rate in HUNT 2 was 71% and contained about 
65 000 participants aged 20 years and older. The control group was considered to be 
representative for age-matched Norwegian males.135 We retrieved data on systolic and 
diastolic blood pressure, the use of antihypertensive medication, body mass index, HDL-
cholesterol and LDL-cholesterol. Blood samples were not available for the control 
subjects for evaluation of serum indices for inflammation and endothelial dysfunction. 
 
2.2 Treatment of TC and HL 
Principles for treatment of TC during 1980 – 1994 and HL during 1980 – 1988 in 
Norway are described in chapter 1.  
 
According to the treatment policies TC patients were divided into four groups: 
1) Surgery only.  
2) Infradiaphragmatic therapy with the use of the dog-leg technique.  
3) Cisplatin-based therapy only 
 35 
4) Cisplatin-based chemotherapy and infra-diaphragmatic radiotherapy. Only one patient 
had received additional mediastinal radiotherapy.  
 
Our HLSs had all received mantle field or mediastinal field only at a dose of median 40.0 
(range 27 – 44) Gy. No subcarinal blocks or cardiac shields were used (Figure 5). In 
Paper III, IV and V 40, 36 and 36 patients respectively were diagnosed with stage I or II 
HL. Fourteen patients were treated with only radiotherapy while the remaining patients 
with risk factors had also received concurrent chemotherapy (ChlVPP/ABOD or ChlVPP 
or ABOD alone). In Paper III, IV and V only 11, 11 and 8 patients respectively had been 
diagnosed with stage III and IV HL. They had been treated with ChlVPP and ABOD or 
ChlVPP only. Table 5 summarizes the different treatment principles in TCSs and HLSs. 
 
2.3 Methods 
Questionnaire 
The questionnaire mailed to TCSs and HLSs consisted of validated instruments and 
sample items, all selected to allow comparison with the general population in Norway. 
Information was obtained on smoking habits, physical activity, educational level, family 
status, medication and the occurrence of diabetes mellitus type I and II. Patients were 
categorized as current smokers or persons who had quit or never smoked, and as 
physically active or inactive. Two questions were used to assess low physical activity (for 
example walking) and high physical activity associated with breathlessness and sweating. 
Physical inactivity was defined as the absence of high physical activity and less than 1 
hour of low physical activity during one week. Patients were categorized to the presence 
or absence of education at university level and into whether they lived alone or were 
married/cohabitant. The patient was categorized to have diabetes according to the 
questionnaire.  
In Paper II we extracted information from the questionnaire answered at FU-2 about first-
time post-FU-1 cardiovascular events (myocardial infarction, stroke, revascularization, 
and hospitalization for heart failure). All self-reported cardiovascular events were 
validated by the patient’s hospital medical record. 
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The Cancer Registry of Norway 
With permission from the Regional Ethical Committee, the Norwegian Directory of 
Health and the Data Inspectorate we received data (type of cancer, date of diagnosis) 
about non-germ cell cancer diagnosed after FU-1 among our eligible TCSs as registered 
by December 2008. Furthermore, there were also data on all deaths as well as the cause 
of death registered after FU-1. Thus, we were able to identify those who died from 
cardiovascular causes. The diagnosis of localized prostate cancer (n = 5) was not 
considered to be a valid event as this malignancy is increasingly detected by PSA 
screening and many of these patients are not at risk of developing invasive cancer and die 
from other causes.  
 
Clinical examinations 
Blood pressure was measured manually or with automatically devices. Weight with only 
light clothing and without shoes and height were registered. Body mass index was 
calculated as weight in kilograms divided by the square of height in meters.  
 
Biochemical analyses 
Non-fasting blood was sampled between 9 am and noon into pyrogen-free, pre-cooled 
vials without additives (serum) or with EDTA as anticoagulant (plasma). The tubes were 
centrifuged at 1,000g for 10 minutes within 30 minutes (plasma) or allowed to clot before 
centrifugation (serum). Because of in vitro production of pro-inflammatory biomarkers 
the application of EDTA was added to all samples in order to impair ex vivo production 
of inflammatory markers. Serum levels of sCD40L were determined by enzyme 
immunoassay (EIA, R&D Systems). Plasma levels of vWF were determined by EIA as 
reported.136  High sensitivity CRP in plasma was determined by a high-sensitive particle-
enhanced immunoturbidimetric assay (Roche Diagnostica) and was analyzed both in FU-
1 and FU-2. Plasma levels of leptin were analyzed by radio immunoassay (Linco 
Research, Inc.). Plasma levels of total cholesterol, low-density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides were measured 
enzymatically on a Roche/Hitachi 917 analyzer (Roche Diagnostics). Serum levels of 
apolipoprotein A-1 (apo A-1) and apolipoprotein (apo B) were analyzed on a Behring 
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Nephelometer Analyzer II (Behringwerke). Plasma homocysteine concentration was 
determined by HPLC.137 Lp(a) in plasma was determined by an immunoturbidimetric 
assay on a Modular platform (Roche Diagnostica). Serum levels of luteinizing hormone 
(LH), testosterone and sex hormone binding globulin (SHBG) were analyzed by 
immunoassays.104 Serum levels of free testosterone were calculated as reported 
elsewhere.138  
 
Echocardiography 
Echocardiography was used to determine valvular dysfunction and cardiac function 
including ventricular dimensions in both systole and diastole. We performed 2-
dimensional (2D) transthoracic echocardiography with a Vivid 7 scanner (GE Vingmed 
Ultrasound). Three consecutive heart cycles from the parasternal, long axis, short-axis, 
apical four chamber, and subcostal views were obtained. The digital loops were stored 
and analyzed by EchoPac software (GE Vingmed Ultrasound). In M-mode we recorded 
measurements of left atrial diameter (LA), left ventricular end-diastolic and end-systolic 
diameters (LVEDD and LVESD, respectively), left ventricular posterior wall (LVPW), 
interventricular septum thickness (IVSd), and LV-SF. Cardiac index (CI) was calculated 
from cardiac stroke volume, heart rate, body height, and body weight. Left ventricular 
ejection fraction (LVEF) was assessed by the modified Simpson’s rule. LVEF and left 
ventricular end diastolic volume were measured only in ECHO 2005. 2D and pulsed 
Doppler echocardiography were used to estimate valvular regurgitation and stenosis 
(mild, moderate, or severe) according to published recommendations.139, 140 Left 
ventricular remodeling was defined as a thinning of ventricular walls and dilatation of the 
ventricle between FU-1 and FU-2. All examinations were carried out according to a 
standardized protocol by physicians and sonographers at the Department of Cardiology, 
and all the data were interpreted by a single experienced cardiologist (Thor Edvardsen), 
blinded for patient history (including the results from FU-1) and treatment. 
The degree of valvular dysfunction was classified according to recommendations from 
the American Heart Association and the European Society of Cardiology.139, 140 Aortic 
stenosis is also graded as mild, moderate or severe based on the valve area, mean 
pressure gradient in systole and the jet velocity during systole.139 
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To analyze changes in the myocardial function we calculated the percent change in 
LVEDD, LVESD, IVSd, LVPW, LV-SF and CI from the first to the second follow-up. 
LV-SF is defined as the percent change in the internal diameter from diastole to systole. 
CI is defined as stroke volume multiplied with the heart rate divided by body surface 
area.  
 
Multidetector computed tomographic scan (MDCT) of the heart 
Coronary artery calcium correlates closely with overall burden of atherosclerotic plaques. 
Quantification of coronary artery calcium has been suggested as a surrogate endpoint of 
coronary artery disease.141-144 Their importance as a risk factor of coronary artery disease 
in in HLSs has not been properly defined. Therefore, all HLSs were examined in a 64-
detector computed tomography unit (GE LightSpeed 64 VCT, GE Healthcare, 
Milwaukee, WI) including a dedicated work-station (Advantage Window 4.3.3).  The 
scan was performed with ultra-fast acquisition time and is electrocardiographic triggered 
near the atrial systole in order to achieve a scan when the heart is moving minimally. The 
acquisition time is only 100 ms producing 3 mm non-overlapping slices. The 
quantification of coronary artery calcium is done by a computerized program 
(SmartScore 3.5, GE Medical Systems, Milwaukee, WI) giving the CACS as both 
Agatston score and volume score. In the 3 mm thick non-overlapping slices a 
hyperattenuated lesion above a threshold of 130 Hounsfield Units indicates the presence 
of coronary artery calcium. Additionally this lesion has to cover an area of at least 1 
mm2.145 The Agatston score was calculated by multiplying the lesion area in every 3 mm 
slice by a density factor derived from the maximal Hounsfield unit following manner: 1 
for lesions whose maximum density were 130 to 199, 2 for lesions 200 to 299, 3 for 
lesions 300 to 399, and 4 for lesions >400.146 With the volume score the input data is 
sampled at several intermediate cross sections between the original 3 mm slices in order 
to reconstruct the precise volume of the atherosclerotic plaques. Total volume or 
Agatston score were calculated as the sum of scores in the left main artery (LMA), left 
anterior descending artery (LAD), circumflex artery (CX) and right coronary artery 
(RCA). The patients were categorized according to the following ranges for volume 
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score; 0, 1-199, 200-999 and ≥ 1000. Even if the methods are slightly different, the 
correlation between the two methods is excellent.147 
The assignment of segments to coronary arterial territories was done in accordance with 
clinical recommendations.148 Three patients underwent percutaneous coronary 
intervention with implantation of a stainless steel stent in 1 coronary artery. Arterial 
segments with stent were excluded from CACS calculation because of the stent artefact. 
The scoring was carried out independently by two experienced radiologists (Rune 
Andersen and Anne Günther). The interobserver variability was 4.7%. 
 
CT angiography of pre-cranial arteries 
Estimation of carotid stenoses by CT angiography has shown a strong correlation with 
the gold-standard conventional catheter angiography.149-151 Furthermore, CT angiography 
displays all extra-coronary arteries included in the radiation field and gives a detailed 
picture of the atherosclerotic burden in HLSs. All patients were examined in a 64-
detector computed tomography scanner (GE LightSpeed 64 VCT, GE Healthcare, 
Milwaukee, WI).  During an i.v. bolus injection of contrast medium (Visipaque 
320mg/ml, 60 ml), a CT volume scan covering the anatomy from the aortic arch to the 
skull base was performed. The native slice thickness of 0.625 mm was reformatted to 2.5 
mm axial, 1 mm coronal and sagittal maximal intensity projection (MIP) slices. The 
degree and extent of atherosclerosis was assessed by an experienced neuroradiologist 
(B.N). For each individual patient, the sites of detectable atherosclerotic abnormalities 
were compared to the radiation field margins by Bård Nedregaard, Alexander Fosså and 
Torgeir Wethal and scored as within field (>1 cm from field boundary) or outside field.  
Vessel lumen diameter measurements were performed in all participants. The minimal 
luminal diameter at the site of an atherosclerotic lesion was measured together with the 
normal luminal diameter of the vessel at the closest adjacent segment to the 
atherosclerotic lesion, from which the percent of luminal narrowing was calculated. 
Atherosclerotic plaques with or without calcifications were specifically registered 
without regard to stenoses.  
In an effort to provide an estimate of the amount of atherosclerosis in the irradiated pre-
cranial arteries we developed a pre-cranial atherosclerosis score (PAS) representing a 
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semi-quantification of pre-cranial artery atherosclerosis. The following pre-cranial 
arteries were scored; the brachiocephalic trunk, the subclavian arteries, the common 
carotid arteries, the carotid bifurcations, the internal carotid arteries, and the vertebral 
arteries. In each of these 11 arteries we calculated if the atherosclerotic lesion had less 
than 5% luminal narrowing (score 1), with 5-30% narrowing (score 2), with 30-50% 
narrowing (score 3) and the presence of >50 % lumen reduction (score 4). A total score 
was then calculated for each patient, ranging between a score of 0 to 44.All arteries were 
equally weighted without respect to differences in the length and normal luminal 
diameter of the vessels included. The subclavian arteries were scored before the departure 
of the vertebral artery. As an alternative measure for pre-cranial artery atherosclerosis we 
dichotomized the patients according to the presence or absence of any degree of 
atherosclerosis in both the internal carotid artery including the carotid bifurcation and at 
the origin of the great arteries from the aorta.  
 
Strain-gauge plethysmography 
Peripheral endothelial function was assessed with a mercury-in-silastic strain gauge 
plethysmography (Hokanson EC6, Bellevue, Washington). This is a non-invasive method 
and several studies have demonstrated an impairment of the endothelial function in 
patients with cardiovascular risk factors.152-154 The endothelium of the arterial vasculature 
is a highly specialized and active tissue which modulates the vascular tone, and release 
signal substances activated during inflammation.155 Endothelial dysfunction precedes the 
development of atherosclerosis and serves as an early marker of CVD.156, 157 Strain-gauge 
plethysmography measured forearm blood flow (ml/100 ml forearm/min). In the supine 
patient the left arm was elevated about 5 centimeters above the heart level. A gauge was 
placed around the widest and most muscular part of the forearm and a cuff was placed 
proximal for the gauge. A venous occlusion pressure of 50 mm Hg was used to measure 
the resting blood flow which was taken as the average of 5 consecutive measurements. 
The cuff was inflated to suprasystolic pressures in exactly 5 minutes to induce ischemia. 
Peak reactive hyperemia was measured immediately (within 4 seconds) after cuff 
deflation using venous occlusive stasis. Peak reactive hyperemia was caused by instant 
relaxation of peripheral resistance arteries mediated by local vasoactive ischemic 
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metabolites like adenosine where contributing factors are NO, prostaglandins and 
activation of ATP sensitive K+ channels 158, 159. The available amount of NO is 
dependent on asymmetric dimethylarginine (ADMA), an inhibitor of endogenous nitric 
oxide synthase. The decreased peripheral resistance leads to an increased shear stress 
caused by the blood flow leading to a secondary release and production of NO. The early 
peak reactive hyperemic flow was taken as a measure of endothelial function. 
 
Composite measures 
We examined other possible risk factors like the metabolic syndrome and hypogonadism. 
The metabolic syndrome has been associated with CVD. 160, 161 The metabolic syndrome 
was defined according to the presence of 3 or more of the following 4 criteria: (1) 
systolic blood pressure ≥130 mm Hg, diastolic pressure ≥85 mm Hg, or use of 
antihypertensive medication, (2) serum triglycerides ≥1.70 mmol/L, (3) HDL cholesterol 
<1.04 mmol/L, and (4) body mass index  ≥30 kg/m2 (a modified definition based on the 
Executive Summary of the Third Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III), 2001).162 The measurement of glucose 
was not included in our modified definition of the metabolic syndrome because of non-
fasting values. Additionally, TCSs  were classified as having hypogonadism if any of the 
following 3 conditions were met: serum testosterone <8 nmol/L, serum LH >12 U/L, or 
regular use of exogenous testosterone.104 Testosterone/LH ratios were calculated for use 
as an additional indicator of gonadal function.  
 
2.4 Statistical analyses 
Data were analyzed using SPSS 12.0 - 14.0 (SPSS Inc) and R 2.1.1 for PC. Mann-
Whitney and Kruskal-Wallis tests were used to compare skewed data, and Chi-square or 
Fisher’s exact tests were used to compare categorical data. The Student’s t test was used 
to compare normally distributed continuous data. The Mann-Whitney test was used for 
highly skewed continuous data. Pearson or Spearman correlation analysis was used to 
investigate the relationships between continuous data (i.e. age-related variables, 
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echocardiographic parameters, lipid-related markers, inflammatory markers, peripheral 
endothelial dysfunction, CACS and PAS).  
 
In Paper I the inter-group comparisons of the inflammation indices hsCRP, vWF and 
sCD40L were adjusted for age, gonadal hormones, lipid-related indices, body mass index 
and systolic and diastolic blood pressure by application of a general linear model that 
used Gamma distributed residuals and a logarithmic link-function.163 This test can be 
described as an expanded ANOVA which takes into consideration possible confounders. 
 
Binary logistic regression was performed to reveal the association between the metabolic 
syndrome (Paper I), aortic stenosis (Paper III), new onset valvular regurgitation (CAD 
(Paper IV), the presence of extra-coronary atherosclerosis (Paper V) and the various 
treatment-related, clinical-related or biochemical indices. Linear regression analyses were 
performed with the percent changes in each of the 6 echocardiographic variables (Paper 
III) and PAS and CACS (Paper V) as dependent variables. Parameters with a p-value 
<0.10 in univariate analyses were included in a final multiple logistic or linear regression 
analysis. A p-value <0.05 was considered statistically significant. Results were given as β 
or odds ratios (ORs) with 95 % confidence intervals. 
 
ROC analyses were used in Paper II to determinate the optimally discriminating CRP 
value for the composite end point of CV event and a second cancer. The identified cut-off 
level was used to construct groups of patients with CRP < 1.5 mg/L and ≥ 1.5 mg/L. The 
cumulative incidence of CVD and a second cancer as separate end-points were then 
computed for these two groups using Kaplan-Meier plots. Additional Kaplan-Meier plots 
were drawn to illustrate the impact of different treatment modalities, separating irradiated 
patients (+/- chemotherapy) from those having surgery and/or chemotherapy. Differences 
in time to event between CRP groups or treatment groups were assessed using log-rank 
tests. Uni- and multiple Cox-regression models were fitted to explore the relation 
between clinically important predictors of a second cancer and cardiovascular events. The 
limited number of each of these end-points allowed only three variables to be included in 
the multiple Cox-regression analyses, all meeting the proportional Hazard assumption. 
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Results of the Cox-regression analyses were presented as hazard ratios (HRs) with 95 % 
confidence intervals (CI). A two-sided p-value <0.05 was considered statistically 
significant. 
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3 RESULTS 
 
Paper I 
In TCSs we examined the implication of the treatment on the inflammatory markers CRP, 
vWF and sCD40L and lipid-related markers (total cholesterol, LDL – cholesterol, HDL – 
cholesterol and triglycerides), which are associated with increased cardiovascular risk 
 
All patients treated with radiotherapy and with a diagnosis of seminoma, had higher 
levels of CRP and soluble CD40 ligand compared to the SURG group. After adjustment 
for cardiovascular risk factors (age, blood pressure, lipid-related markers, gonadal 
function) CRP and sCD40L was respectively, 0.35 (± 0.13) mg/L and 0.27 (± 0.08) 
pg/mL (p < 0.01) higher in the radiotherapy group as compared to patients treated with 
surgery only.  
 
Patients who had received chemotherapy had lower levels of high density lipoprotein 
cholesterol and an increased apolipoprotein B/apolipoprotein A-1 ratio than those treated 
with surgery only (p < 0.001 and p = 0.01 respectively). In the chemotherapy group the 
number of men with HDL cholesterol levels less than 1.04 mmol/L exceeded that 
observed in the age-matched reference control group (41.4 vs. 29.6 %, p<0.001. The 
prevalence of the metabolic syndrome was only 6.3% in patients treated with surgery. In 
contrast; this prevalence was 15.2% in the radiotherapy group and 17.6% in patients 
treated with chemotherapy. Using the matched control groups as a reference, we observed 
an elevated prevalence of the metabolic syndrome among chemotherapy-treated patients 
(p = 0.07) and a low prevalence among those who were treated with surgery only (p 
<0.01). Additionally, hypogonadism was significantly more prevalent in the 
chemotherapy group (13%) compared to the surgery group (5%, p = 0.01).  
 
Paper II 
The aim was to examine if inflammatory markers, lipid-related markers or traditional 
clinical risk markers measured during the follow-up of TCSs were able to predict 
cardiovascular events and second cancer. The post-FU-1 development of a non-germ cell 
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cancer or a first-time cardiovascular event represented the end-point. After FU-1 31 
(5.3%) of 586 patients developed non-germ cell cancer (excluding localized prostate 
cancer) while 28 (4.9%) developed CVD. Cox regression analyses showed that patients 
with CRP ≥ 1.5 mg/L had 2.21 (95% CI 1.04 – 4.70) times higher risk of developing non 
germ cell cancer and 2.79 (95% CI 1.22 – 6.34) times higher risk for CVD compared to 
patients with a CRP < 1.5 mg/L at FU-1. Four patients developed non-germ cell cancer 
within 2 years after the measurement of CRP. The estimated risk of a second cancer was 
2.16 (95% CI 0.97 – 4.82) after excluding these patients. There was a strong relationship 
between CRP-levels at FU-1 and FU-2 (Spearman r = 0.59, p < 0.001). 
 
Radiotherapy was associated with 2.56 (95% CI 1.19 – 5.51) times higher risk for 
developing non-germ cell cancer in comparison to patients treated with surgery with or 
without chemotherapy. Additionally, after the exclusion of the 22 patients who were 
registered to be treated with both chemotherapy and radiotherapy, treatment with infra-
diaphragmatic radiotherapy only was associated with increased risk of a second cancer 
(HR 2.29 (95% CI 1.03 – 5.07)). Radiotherapy was not associated with CVD (HR 1.40 
(95% CI 0.67 – 2.95). 
 
Paper III 
This paper tested if the long-term development and evolution of valvular dysfunction in 
irradiated patients were independent of a previous diagnosis of valvular regurgitation 
observed during follow-up of HLSs. Furthermore, we tested if the use of anthracyclines 
was associated with the development of myocardial dysfunction even between FU-1 
(median 10 (5 – 13) years after treatment) and FU-2 (median 22 (11 – 27) years after 
treatment). Median age at diagnosis was 26 years (range 14 – 42 years), and 67% of the 
participants were women. Thirty-six patients received additional chemotherapy. 
Antracyclines were given to 28 (55%) of the patients  
 
The second echocardiographic study at FU-2 demonstrated that 10 out of 27 (37%) 
patients with only mild or no aortic or mitral regurgitation at FU-1 had developed 
moderate regurgitation in either or both the aortic or mitral valve. Eight of 24  (33%) 
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patients with moderate (n=23) or severe (n=1) regurgitation in the aortic or mitral valve 
at FU-1 had progressed to severe regurgitation, developed moderate regurgitation in a 
previously normal or mild regurgitant valve or had received valvular replacement. A total 
of  20 of all patients (39%) patients had developed mild to severe aortic stenosis and three 
patients had received valvular replacement. Of those who had aortic stenosis 13 were 
mild, 3 moderate and 4 severe. The estimated aortic valve area among the 20 patients was 
median 1.6 (range 0.6 – 3.2) cm2, and the median valvular gradient was 11 (range 5 - 45) 
mm Hg.  
 
The appearance of both the aortic and mitral dysfunctional valve was dominated by 
different degrees of degeneration including leaflet thickening, reduced leaflet movements 
and calcification. Calcification was observed among those with moderate/severe stenosis 
or regurgitation. Regurgitation was observed in the first decade after treatment, while 
aortic stenosis first became apparent during the second decade after treatment. New-onset 
valvular regurgitation did not demonstrate any relation to clinical or treatment related 
parameters. Binary logistic regression with the presence of aortic stenosis as the 
dependent variable failed to show any relationship with chemotherapy, the presence or 
absence of valvular regurgitation at FU-1 or any of the registered clinical parameters.  
In a multiple linear regression the use of anthracyclines predicted left ventricular 
remodeling between FU-1 and 2 compared to those who did not receive anthracyclines. 
Left ventricular end systolic diameter increased (ß 0.09 (95% CI 0.01 – 0.17), p = 0.04) 
while the thickness of the left ventricular posterior wall (ß - 0.18 (95% CI -0.33 – -0.03), 
p = 0.02) and interventricular septum (ß – 0.16 (95% CI - 0.30 – -0.03), p = 0.02) 
decreased.  
 
Paper IV 
This study examined the relationship between CAD and CACS in forty-seven HLSs treated 
with mediastinal radiotherapy 22 ± 3 years earlier. Total volume score was higher in 7 
patients (15%) with verified CAD (median 439 (range 8 – 2057) compared to those 
without (median 68 (0 – 767), p = 0.022). LMA, LAD and CX had a higher CACS in 
patients with verified CAD compared to patients without, whereas CACS for RCA was 
 47 
comparable in the 2 groups. Ten patients had volume score above 200; five had 
undergone revascularization of the coronary arteries.  
 
Multiple logistic regression analysis adjusting for the presence of aortic stenosis, pro-
BNP, gender and age at diagnosis of HL revealed that CACS was the only parameter 
associated with verified CAD with an odds ratio of 2.1 (95% confidence interval 0.98 – 
4.94, p = 0.057) for every 200-U increase in CACS. Use of an Agatston score yielded 
similar results, providing an excellent correlation with volume score (r = 0.996, p < 
0.001).  
 
Paper V 
The objective was to examine the association between the extent of atherosclerosis within 
the radiation field including the coronary arteries, peripheral endothelial dysfunction, 
circulating markers of inflammation and traditional risk factors measured at FU-1. A total 
of 141 atherosclerotic lesions were found within the radiotherapy field in the 43 HLSs 
and 120 (85%) of the lesions were calcified.  
 
Multiple linear regression analyses showed that only cholesterol measured at FU-1 was a 
predictor of both PAS (β 3.29 (95% CI 1.90 – 4.69), p < 0.001), CACS (β 308 (95%CI 
213 – 403), p < 0.001) and a decrease in peripheral endothelial function (β 2.74 (95%CI 
0.47 - 5.01, p = 0.02). Multiple logistic regression analyses showed that cholesterol 
measured at FU-1 was the only predictor of pre-cranial atherosclerosis (OR 3.86 (95% CI 
1.24 – 12.01), p = 0.02). 
Multiple linear regression analyses showed that for every increase in CACS by 100 units 
there was an increase in PAS by 0.72 (95%CI 0.43 – 1.01), p < 0.001). Furthermore, 
every increase in peripheral endothelial function by 1 ml/100 ml forearm/min was also 
associated with a decrease in PAS by 0.21 (95%CI 0.03 – 0.38), p = 0.02). At FU-2 an 
increase in CACS by 100 units (OR 2.64 (95% CI 1.33 – 5.26, p = 0.01)) was associated 
with the presence of pre-cranial atherosclerosis.  
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4 DISCUSSION  
 
4.1 Methodological considerations 
4.1.1 Epidemiological studies 
Epidemiology deals with the variations of incidence and prevalence of diseases in 
different populations and aims to identify etiological factors which determine this 
variation.164 Epidemiologic studies such as cross-sectional studies, longitudinal studies 
and case-control studies are used to measure the effect of individual and population based 
interventions. Cross sectional and longitudinal studies are observational, i.e. we do not 
control for any other risk factors when the patients are included except for the exposure 
that we are interested in. A cross sectional design is useful to determine the prevalence of 
a relatively frequent disease or define risk factors for a disease across groups. Any causal 
relationship can not been defined. Nevertheless, cross sectional studies are useful to 
identify possible risk factors and generate hypotheses about causes of a disease. Risk 
factors may be difficult to identify because of recall bias. Longitudinal studies are 
suitable to estimate the incidence of a disease and establish a causal relationship between 
exposure and disease.  
 
4.1.2 Systematic errors (Bias)  
Our results may be hampered by bias which is divided into selection bias, information 
bias and confounders. Together they constitute the internal validity of the studies. Internal 
validity describes whether the results can be representative for the study population. 
 
4.1.2.1 Selection bias 
In Paper I we included all surviving and disease free men who had been treated for 
unilateral TC at the NRH and had not developed another malignancy at the time of FU-1. 
TCSs above the age of 60 years and those treated with both radiotherapy and 
chemotherapy were excluded from Paper I. Of those eligible for the study 75% 
participated. Non-responders and responders displayed similar baseline characteristics 
(age, treatment, histology indicating that the participants were representative for the 
cohort of TCSs treated at the NRH. However, non-responders may differ from responders 
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on characteristics not measured at baseline or follow-up. Non-responders may express 
more morbidity with impaired quality of life and depression than responders and are less 
likely to appear at a follow-up study. This phenomenon is well known as up to 10% of 
the non-responders in the HUNT survey did not attend due to immobilization.135  
In Paper II we included patients treated with chemotherapy (n=221), radiotherapy 
(n=211) and the combination (n=22). The latter group was difficult to analyze separately 
due to low sample size and the possible interaction between chemotherapy and 
radiotherapy. Since the goal in Paper II was to examine the predictive value of hsCRP 
independent of the treatment group we included this small group as well. Patients without 
a CRP value did not differ from those with a CRP with respect to age at FU-1, type of 
cancer treatment, systolic and diastolic blood pressure and current smoking. We therefore 
believe that the results reported by this study may be representative for Norwegian TCSs. 
The participants in Paper I and II represented over 50% of the Norwegian TCSs included 
in a nation wide study and are comparable to the whole cohort of Norwegian TCS.76 
 
In Paper III we included HLSs who had no, mild or moderate valvular regurgitation at 
FU-1. This may have caused a selection of those who also otherwise are vulnerable to 
radiotherapy and likely to develop atherosclerosis, cardiovascular risk factors and 
cardiovascular disease itself. However, the progression and development of valvular 
regurgitation and stenosis were independent of their valvular status at FU-1. Furthermore, 
the prevalence of CVD in our 51 HLSs were comparable to those presented by other 
studies.57, 59, 63  
 
The external validity of the results is probably high, both for TCS and HLSs. The age at 
which the cancer was diagnosed and the symptoms and the histology of the cancer 
showed typical characteristics, and the treatment they have received were according to 
the guidelines at that time as presented in the Method section. Nevertheless, the patients 
in the presented Papers consist of a homogenous ethnic group (Caucasians). Furthermore, 
also socioeconomic factors are important and interact with the incidence and prevalence 
of TC and HL, the histopathology, the response to treatment and may eventually have an 
impact on the long-term consequences of the treatment. The HLSs in the present studies 
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are mainly women making it difficult to generalize the results to men and the small 
sample size indicate that we have to be careful to make conclusions for HLSs in general. 
In paper I we used controls from the Nord–Trøndelag County. Even though it has been 
reported that the controls are fairly representative of the Norwegian population, they did 
differ from our population of TCSs who more often had higher education, were non-
smokers and were less likely to be living alone.135 This may have caused an 
overestimation of the presence of risk factors in controls compared to our TCSs. The 
controls were characterized by low HDL cholesterol and an increased prevalence of the 
metabolic syndrome compared to patients treated with only surgery. 
In Paper III, IV and V there was no control group of healthy individuals. In the 
Framingham population between 40 and 60 years old the prevalence of moderate or 
severe mitral regurgitation in both men and women was 1%, and the prevalence of 
moderate or severe aortic regurgitation in men and women was only 0.4 and 0.1%, 
respectively.165 In Lund et al’s study reporting on the results from FU-1 31% HLSs had 
developed a moderate regurgitation while none of the 40 age- and gender matched 
controls displayed moderate valvular regurgitation.62 
 
4.1.2.2 Information bias 
A systematical misclassification of measurements is regarded to be of minor importance 
with variables measured at the out-patient clinic or at hospital. These variables included 
weight, height (for the calculation of body mass index) and biomarkers (CRP, vWF, 
sCD40L, cholesterol, gonadal hormones etc) where the issue of reliability probably is 
more important. All non-fasting samples were stored at -70°C and thawed less than three 
times. This procedure decreased the influence which may be caused by temperature, 
storage time and freeze and thaw cycles as biomarkers are relatively unaffected by up to 
three freeze and thaw cycles. Enzyme linked immunosorbent assays (ELISAs) were 
measured with both inactive and active forms of sCD40L and vWF and the measured 
levels can not be compared with the levels measured in other studies as the unique 
recognition profile of the antibodies will differ between kits from different manufactures. 
The intra- and inter-assay coefficients of variation obtained in our laboratory were less 
than 10% for all biochemical assays.  
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In TCSs the blood pressure was measured only once while the blood pressure measured 
in the controls from HUNT2 was given as the mean of the 2nd and 3rd measured systolic 
and diastolic blood pressure. This may cause an overestimation of the blood pressure 
among TCSs when compared to the controls. An additional problem with TCSs 
compared to controls is that there are preliminary results indicating that TCSs more 
frequently visit the general practitioners compared to the general population with the 
consequence that the use of hypertensive medication (and possibly cholesterol 
medication) is more frequent among TCS than the controls (Dahl, in preparation). 
 
Information on education, smoking, physical activity and diabetes was assessed only by 
the questionnaire for TCSs and by a personal systematic interview of HLSs. Generally 
people often describe themselves as healthier than they actually are and the expressions 
of risk factors in the individuals may change over time; some smokers quit, other 
becomes more or less physical active. Additionally, the problem of misclassification may 
be due to poorly defined questions in the questionnaire. For example, the questions 
regarding physical activity could be more specified.  
 
During the work with the results from FU-1 in the TCSs we decided to analyze whether 
there were any treatment related differences in the clustering of cardiovascular risk 
factors. Therefore, we decided to use a modified definition of the metabolic syndrome. 
Since the blood samples were not collected in the fasting state we did not use elevation of 
serum levels of fasting glucose as a criterion. The use of other criteria for this syndrome 
had perhaps yielded other estimates of the prevalence of this syndrome and the use of 
non-fasting triglyceride values may have caused an overestimation of the metabolic 
syndrome incidence. However, this would be expected to introduce similar amounts of 
error into the analyses of both our cancer survivors and the HUNT control group since 
only non-fasting triglyceride values was available for the controls. 
 
In Paper II we used are under the curve analyses to find the optimal cut off for the level 
of hsCRP which was best suited to identify cardiovascular disease and second cancer. A 
pitfall with this assumption is that the cut off is “designed” for this study population and 
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may not be applicable to other groups of TCSs. However, previous studies and guidelines 
have demonstrated increased risk of CVD or cancer with the use of a cut-off ranging 
from 1 - 3 mg/L which make our cut-off at 1.5 mg/L reasonable.121, 122, 166 In Paper II the 
use of the alternative cut offs 1 and 3 mg/L yielded similar results for the prediction of 
cardiovascular events, but there was only the cut off at 1.5 mg/L which was able to 
identify TCSs with a higher risk a second cancer. 
 
In Paper III the classification of valvular regurgitation was performed according to 
recommended guidelines which have mainly been unchanged since 1993. 
 
In Paper V it is important to emphasize that the presented score only gives a semi-
quantitative estimate of the pre-cranial atherosclerotic burden. PAS does not take into 
account that the volume of the arterial segments included in the score is very different. 
For example, a defined plaque lesion may be given a low score if present in the 
volumetric large common carotid artery but a high score in the volumetric small vertebral 
artery. PAS can not be regarded as a parameter to define those who are at an elevated risk 
of cerebrovascular disease, since all arteries are equally weighted and a relatively small 
soft non-calcified plaque in the vertebral artery may be more clinically important than a 
calcified lesion causing stenosis in the common carotid artery. However, we consider 
PAS to give an approximate estimate of the atherosclerotic burden in the pre-cranial 
arteries, which is of importance in the risk estimation of CVD. Importantly, although not 
validated, the use of either a score or a dichotomization of atherosclerotic lesions to 
describe the extent of extra-coronary atherosclerosis yielded similar results. 
 
Peripheral endothelial function was assessed by strain-gauge plethysmography. The 
method is often combined with the use of intra-arterial administration of endothelial 
dependent and independent vasodilators. Nevertheless, our use of an ischemic stimuli and 
the subsequent measurement of peak reactive hyperemia without intra-arterial infusion of 
vasoactive substances was simple and reproducible. The measurement of flow-mediated 
vasodilatation in the brachial artery by ultrasound could have increased the diagnostic 
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sensitivity of endothelial function and is today regarded as the most sensitive method to 
define endothelial dysfunction in conduit vessels.167  
 
4.1.2.3 Confounders 
Before attributing any difference in outcome between the exposure groups to the 
exposure itself it is important to examine whether the exposure-outcome association has 
been affected by other factors that differs between the exposure groups and which may 
affect the outcome.168 Such factors are said to confound the association of interest. To 
solve the problem with confounding multiple regression analyses or stratification are 
used. 
 
Hypogonadism and low testosterone are associated with endothelial dysfunction, the 
metabolic syndrome, inflammation and cardiovascular disease.112, 113 Low testosterone 
correlated with the metabolic syndrome and a reduced HDL cholesterol. Because it has 
been demonstrated that reduced fertility and hypogonadism may be evident in TCSs even 
before the diagnosis and treatment of TC, we can not rule out that atherogenic lipid 
changes and inflammation observed in TCSs during follow-up may be due to the 
phenotype and not to the treatment. Several possible confounders that were not adjusted 
for (education, smoking, physical activity, civil status) may have affected the differences 
between HUNT controls and TCSs in the prevalence of the metabolic syndrome and its 
components.  
 
The fact that HLSs were informed about their valvular regurgitation in FU-1 may 
theoretically influence the patient’s behavior and caused life-style changes thus reducing 
their risk of further progress of valvular dysfunction. We have no information about 
eventual post-FU-1 life style adjustments of life style or medical treatment in our 
patients. No known life-style changes will change the natural course of valvular disease. 
Treatment of hypertension has been suggested to slow the progression of aortic stenosis. 
Conversely, patients without or with only mild regurgitation in 1993 may have paid less 
attention to lifestyle and cardiac symptoms, provoking an acceleration of the disease 
course. This suggestion is not supported by our data: Patients without or mild compared 
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to moderate regurgitation showed similar characteristics regarding comorbidites, cardiac 
risk factors and intervention for hypertension and hypercholesterolemia. We therefore 
believe that our longitudinal findings to a large extent mirror the “natural course” of 
valvular function after mediastinal radiotherapy for HL. Additionally, the small sample 
size of HLSs gave some restrictions on the ability to adjust for confounding variables. 
 
4.1.3 Reliability 
The precision or the possibility of random error is small with a large sample size. In 
Paper I 589 TCS were analyzed for inflammatory and lipid-related markers. The intra- 
and inter-essay coefficients of variations for the measured biomarkers were less than 10% 
for all assays. The use of MDCT has demonstrated a mean inter-examination variability 
of 4 ± 2%, and our interobserver variability was only 4.7%.169 As previously stated CT 
angiography has demonstrated a strong correlation with conventional cathether 
angiography in the estimation of carotid lesions.170 With respect to strain-gauge 
plethysmography the intraobserver variability for the resting values was 14%.  Taken 
together, the reliability of the applied methods was considered as good.  
 
4.2 Appraisal of the main findings 
4.2.1 Cancer treatment and atherosclerosis 
Radiotherapy 
In Paper I the treatment of TC can be considered to be related to long-term biochemical 
cardiovascular risk factors by different pathways: Radiation treatment was followed by 
elevated serum markers of chronic inflammation and endothelial dysfunction, whereas 
chemotherapy was followed by the development of atherogenic lipid changes and of the 
metabolic syndrome. In Paper V HLSs treated with radiotherapy 20 years earlier were 
characterized by extensive and typically calcified atherosclerotic lesions affecting all 
arteries within the radiation field accompanied by peripheral endothelial dysfunction. 
These findings were presaged by elevated cholesterol measured 12 – 15 years earlier at 
the first follow-up. 
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Several studies have demonstrated long-term regional effects of radiotherapy on the 
vascular system, including accelerated development of atherosclerosis and fibrosis in the 
irradiated arterial segments and also activated endothelium and decreased endothelium-
dependent vasodilatation.69, 71, 171 We demonstrate that inflammatory indices in our study 
were elevated up to 20 years after large-field radiotherapy possibly triggered by the 
radiation  causing a self-perpetuating process of inflammation in the endothelium. CRP, a 
marker of general inflammation, was elevated above 2 mg/L in 24 (51%) of our HLSs. 
Furthermore, CRP was higher in TCSs treated with radiotherapy as compared to those 
treated with chemotherapy or only surgery. The level of CRP was not associated with in-
field atherosclerosis and peripheral endothelial function in HLSs. A possible relationship 
can not be excluded because of the small sample size. The augmentation of CRP could be 
enhanced by several other risk factors as outlined in Figure 7. 
 
Figure 7 Conditions associated with increased CRP 
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vWF is regarded as a marker of endothelial damage. An in vitro study has shown that 
vWF is released from isolated vessels early after irradiation but there is conflicting 
evidence whether vWF is a marker or a cause of CVD.116, 172-174  We observed an 
association between vWF and peripheral endothelial dysfunction as well as pre-cranial 
atherosclerosis. In the TCSs vWF was elevated in patients treated with radiotherapy 11 
years after the treatment compared to patients treated with chemotherapy or only surgery. 
However, this association was not significant after adjusting for other risk factors.  
 
CRP↑ 
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An indirect toxic effect of radiotherapy is suggested by the long-term increase in CRP, 
vWF and sCD40L. Elevated levels of sCD40L found in TCSs indicate that this process 
may also include platelet activation and thus not only limited to irradiated sites. vWF 
may be an important link to explain the association between in-field atherosclerosis and 
peripheral endothelial dysfunction outside the radiation field. In-field endothelial 
inflammation with the induction of various cytokines and vWF may cause long-term 
endothelial dysfunction outside the radiotherapy field. Previous studies have shown 
impairment of endothelial function in irradiated arteries a few weeks after irradiation for 
head and neck cancer as well as several years after irradiation for breast cancer, but the 
impairment was only found within the radiation fields.72, 73 We demonstrate an 
association between atherosclerosis within the radiotherapy field and peripheral out-of-
field endothelial dysfunction more than 20 years after mantle-field radiotherapy. 
Although the clinical significance of the peripheral endothelial dysfunction measured in 
our cohort of HLSs is difficult to assess, it may shed light on mechanisms involved in 
radiation induced atherosclerosis. It is tempting to speculate that local inflammatory and 
endothelial processes within the radiotherapy field cause systemic effects mediated by 
elevated circulating molecules or that it is associated with the finding of previously 
elevated cholesterol levels. 
. 
Traditional risk factors and especially cholesterol may be of importance to explain why 
some HLSs seem to be at an increased risk of developing atherosclerosis. The finding 
that elevated cholesterol levels a few years after radiotherapy predicted later 
atherosclerosis in HLSs, affecting both the coronary and pre-cranial arteries, is of 
particular importance. Aleman et al found a significant association between 
hypercholesterolemia and the risk of CAD in HLSs.57 Furthermore, it has been 
demonstrated that statins may reduce the inflammatory markers and improve the 
endothelial function in patients treated with radiotherapy.175, 176 This may imply that HL 
patients should be screened for hypercholesterolemia and receive statins early prior to 
radiotherapy. Furthermore, there was a close association between cholesterol at FU-1 and 
endothelial dysfunction at FU-2. This may suggest that the combination of high 
cholesterol and endothelial dysfunction in irradiated patients reflects a phenotype with an 
 57 
increased risk of atherosclerosis. Radiotherapy may further aggravate this disposition as 
demonstrated in this study. 
There is an ongoing debate whether measurements of individual CRP values will give 
additional information beyond what is provided by the traditional risk scores. Recently, 
there has been demonstrated that biomarkers like CRP and N-BNP were not better than 
traditional risk factors.177 In contrast, our study suggests that CRP obtained 6-9 years 
earlier may assist in identifying TCSs with increased risk of developing CVD. A CRP 
level ≥ 1.5 mg/L was associated with almost three times higher risk of CVD compared to 
survivors without elevated CRP levels during a follow-up of 10 years. CRP was superior 
to traditional risk factors in predicting cardiovascular events. Although, the positive 
predictive value of CVD was only 10%, the high negative predictive value of 97% may 
indicate the usefulness of CRP as a first screening test to identify those with an elevated 
risk of CVD. Used together with other risk markers of CVD it may be possible to 
improve the test battery to identify individuals at risk of premature CVD who might 
benefit from primary prophylaxis with statins. Oncologists have increasingly discussed 
the need of life-long monitoring of TCSs, at least of high-risk TCSs. However, no 
biomarker has been identified in TCSs at risk of a second solid cancer or a CVD event. 
Paper II suggests that CRP may be such a predictive factor. 
 
 Radiotherapy contributes to CVD also when given only infra-diaphragmatically and has 
been shown to be the most important etiological factor for a second malignancy.48, 52 
Although we demonstrated increased levels of inflammatory activation in radiotherapy-
treated TCSs, we were unable to show that radiotherapy was associated with the 
incidence of CVD. This may be explained by the fact that the radiotherapy field only 
covers the apex of the heart. Thus, the heart receives limited radiation and the doses are 
lower as compared to HL patients who had been treated with mediastinal radiotherapy at 
a dose of approximately 40 Gy. Furthermore, the limited number of cardiovascular events 
within each treatment group and the short follow-up since CRP measurement perhaps 
reduced the possibility to reveal an association between radiotherapy and CVD.  
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Prior radiotherapy was a risk factor of a second cancer development in TCSs. TCSs with 
a CRP level ≥ 1.5 mg/L at FU-1 had more than twice as large risk for developing non-
germ cell cancer compared to those with CRP < 1.5 mg/L. The mechanism for a second 
cancer is not clearly defined but may be due to radiation-induced genetic mutations and 
long-term subclinical inflammation induced by infra-diaphragmatic radiotherapy in TCSs 
.178 Our results may be confounded by patients who already had asymptomatic cancer at 
the time of CRP measurement or incidental elevation of CRP due to environmental 
infections. Allin et al demonstrated that the association between CRP and cancer was 
attenuated after excluding patients diagnosed within 2 years after CRP measurement.124 
In our study only 4 patients were diagnosed with non-germ cell cancer within 2 years 
after CRP measurement. After the exclusion of these patients CRP ≥ 1.5 mg/L was still 
associated with future cancer, even if this association was attenuated. 
 
Chemotherapy - cisplatin 
Cisplatin-based chemotherapy is today considered to be a possible factor in the 
development of premature atherosclerosis and CVD.48, 52, 77 Our data on the lipid-related 
markers and the metabolic syndrome is in accordance with other studies demonstrating 
that hypertension, hypercholesterolemia and the metabolic syndrome are frequently 
observed among TCSs treated with cisplatin and may contribute to the increased risk of 
CVD.76, 77  Criticism has recently been raised against the concept of the metabolic 
syndrome, because there are no clear additive effects between the different descriptors of 
the syndrome beyond the contribution of diabetes.179, 180 In the present study the 
metabolic syndromes was primarily characterized by reduced HDL cholesterol levels. 
Low testosterone was found to correlate significantly with the metabolic syndrome. In the 
study group as a whole we found a significant correlation between serum levels of 
testosterone and HDL cholesterol, suggesting that low testosterone levels in TCSs at least 
partly can contribute to the metabolic disturbances in these individuals.  
 
The role of inflammatory markers with regard to atherosclerosis after treatment with 
chemotherapy is still undefined. In contrast to our study, previous studies have observed 
that chemotherapy and not radiotherapy is associated with inflammatory markers in 
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TCSs.87, 88 An increase in vWF and intima-media thickness has been observed within 10 
weeks after the completion of chemotherapy.87 Furthermore, another study showed that 
after a median follow-up of 7 years CRP and vWf levels tended to be higher after 
chemotherapy combined with surgery than after surgery alone.134 However, these studies 
are hampered by small sample size and/or short observation time. TCSs treated with 
radiotherapy were not included in these studies. We can not rule out that chemotherapy 
may induce an inflammatory process in TCSs as suggested by other studies.88, 134 TCSs 
treated with chemotherapy was in our study characterized by low HDL cholesterol. HDL 
has anti-inflammatory and endothelial protective properties. Low HDL may reflect a 
dyslipidemic genotype or be secondary to chemotherapy and subsequently aggravate 
endothelial dysfunction.85, 181 Thus, it may be hypothesized that persistent subclinical 
endothelial inflammation after radiotherapy and/or chemotherapy, with on-going 
activation of cytokines, may represent a common link between local or systemic 
cytotoxic treatment and the development of cardiovascular events also in TCSs.  
 
The role of cisplatin-based chemotherapy in the development of second solid cancer is 
suggested in a previous study but is less obvious compared to the increased risk of second 
cancer observed after radiotherapy; probably due to short observation times.54 Cisplatin 
can be demonstrated in serum or urine of TCSs more than 10 years after their 
chemotherapy.84, 182 We were not able to demonstrate that the TCSs treated with 
chemotherapy were at risk of developing a second cancer compared to those treated with 
only surgery. 
 
4.2.2 Cancer treatment and cardiovascular disease 
Both inflammatory markers and traditional risk factors may be of importance when 
considering the increased risk of CVD in TCSs as well as HLSs..47-51.56-63 Even though, 
several of these reports indicate that CVD more often affects HLSs who have an 
increased risk of CAD, congestive heart failure, valvular disease and constrictive 
pericarditis. HLSs remain at increased risk of CVD more than 20 years after the treatment 
and our prevalence of CAD (15%) is comparable with that observed in other studies. 183-
186 Radiotherapy may exert a direct toxic effect on the heart and the great arteries which 
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is aggravated by the concurrent use of anthracyclines. The infra-diaphragmatic 
radiotherapy used to treat TC includes only the apex of the heart and the patients receive 
lower doses of irradiation. However, the inclusion of the apex in the infra-diaphragmatic 
field may to some extent explain the increased risk of cardiovascular disease after 
infradiaphragmatic radiotherapy for TC.47, 48, 51  
 
Coronary artery disease 
There is evidence that CACS is an independent and reliable predictor of CAD in 
asymptomatic individuals although absence of calcification does not exclude coronary 
events.187, 188 Paper IV demonstrates a strong relationship between the severity of 
coronary artery calcification and CAD requiring treatment in HLSs. A volume score > 
200 was associated with verified CAD in 5 of 10 individuals. Coronary angiography was 
not performed as a routine in asymptomatic patients. Therefore our number of patients 
with verified CAD may underestimate the true proportion of HLSs with CAD. 
Asymptomatic patients with a score above 200 had calcium deposits mainly in RCA and 
CX, vessels which are less likely to cause symptoms. Coronary angiography in these 
patients may have diagnosed more patients with angiographically significant coronary 
artery stenoses. Coronary artery calcification after radiation therapy for HL has 
previously been quantified in only 9 HLSs with no history of CAD. Volume score was 
above 200 in 5 of these patients and angiography confirmed > 50% stenosis in 4 of 
these.189.Two patients in our study with verified CAD and a CACS at 8 and 46 
respectively could not be properly scored because of a stent implantation which makes 
the culprit vessel unsuited for calcium quantification. Therefore the most pathologic 
segment of the coronary tree of these patients was excluded from CACS.  Inclusion of 
these patients before stenting of the stenosed artery would have strengthened the 
correlation between CACS and CAD. Only 17% of our patients (8 of 47 HLSs) presented 
with a coronary calcium score of zero. In a slightly older population referred to MDCT 
angiography, 46 % had zero coronary calcium 190. Our patients without coronary artery 
calcium did not report symptoms of CAD. This may suggest a favourable prognosis but a 
low CACS does not exclude CAD as has been shown in non-irradiated patients 191.192 
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However, this may be different in irradiated patients where coronary calcification seems 
to be a more prominent feature.  
 
Stroke 
Seven significant stenoses (≥ 50% of luminal narrowing) were revealed in 6 of 43 (14%) 
HLSs studied in the present study. Although only 3 patients reported a previous history of 
cerebral ischemia or stroke, a long-term increase in the incidence of stroke can not be 
excluded. A recent study by de Bruin et al demonstrated an incidence ratio of stroke at 
2.2 17 years after treatment in HLSs compared to the general population.82 Our findings 
are in line with studies demonstrating increased intima-media thickness and more 
subclavian and carotid stenosis in HLSs.193, 194 Also for head and neck cancer patients 
treated with radiotherapy, an increased incidence of stroke has been reported, but these 
patients are generally older and have received higher doses of irradiation than HL 
patients.195 It is important to emphasize that a total of 85% of the atherosclerotic lesions 
in the pre-cranial arteries were calcified and that the coronary arteries in HLSs contained 
highly calcificated plaques. The association between radiotherapy and the presence of 
calcified atherosclerotic lesions may suggest a more clinically stable stenosis with less 
risk of a rupture, which may explain the low number of strokes among our HLSs. 
 
Congestive heart failure 
Our results consistently demonstrated that treatment with low to intermediate doses of 
anthracyclines were associated with thinning of the ventricular walls and ventricular 
dilatation compared to radiotherapy alone or radiotherapy combined with chemotherapy 
without anthracyclines. This is of relevance for the treatment principles of stage I and II 
HL today, as short term anthracycline-based chemotherapy followed by involved field 
radiotherapy (frequently encompassing parts of the mediastinum) is considered standard 
treatment for early stage disease in most Western countries.196 To our knowledge this is 
one of the first studies to document a progressive unfavorable effect of anthracyclines on 
cardiac function two decades after the treatment of adult onset cancer. Studies are 
underway which will evaluate the time-dependent changes in cardiac function and 
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examine the effect of an ACE-inhibitor on myocardial performance, mainly in children 
with different types of leukemia and lymphomas.197, 198 
 
Valvular dysfunction 
In Paper III we demonstrate a progressive valvular deterioration after mediastinal 
radiotherapy. Aortic and mitral regurgitation was a dominant finding in the first decade 
after treatment while aortic stenosis seems to develop in the second decade after 
treatment for HL. The rates are higher compared to other studies and may be due to 
differences in the treatment, classification of valvular dysfunction and the length of the 
follow-up.56, 58, 61 Nevertheless, our data suggest that deterioration of valvular 
regurgitation and the development of aortic stenosis are slow dynamic processes that may 
appear more than 10 years after the diagnosis of HL. Importantly we could show that 
aortic stenosis developed during the second and third post-treatment decade. No clear 
associations were observed between the development of valvular dysfunction and the 
cholesterol level measured at FU-1 and the cholesterol level and inflammatory markers 
measured at FU-2. Previous studies have documented an association between cholesterol 
and aortic stenosis but the SEAS study did not observe any beneficial effect of statin 
treatment on the progression of aortic stenosis.199 However, the occurrence of CVD was 
decreased. It is therefore likely that radiotherapy was the dominant cause of valvular 
dysfunction in the present study and that cholesterol is a more important contributor of 
atherosclerosis in the irradiated coronary and pre-cranial arteries.  
 
Radiotherapy may directly damage the valves and cause fibrotic thickening, retraction, 
and calcifications.69 More recently decreased levels of endothelial progenitor cells have 
been suggested to reduce endothelial regenerative capacity and to contribute to the 
progression of degenerative aortic stenosis.200 It is unknown whether radiotherapy may 
reduce endothelial regenerative capacity in HLSs. Though valves are normally avascular, 
cellular injury may cause fibrosis and stimulate secondary angiogenesis and calcification. 
Our results suggest that valve retraction is the predominant early change that causes 
valvular regurgitation, and it takes as long as 20 years to develop thickened, calcified 
valves that finally may result in stenosis. Higher pressure on the left side of the heart 
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most likely explains the observation that the aortic and mitral valves were more often 
affected than the tricuspid or pulmonary valves, and that stenosis is primarily observed in 
the aortic valve.56, 58, 61 Previous reports have demonstrated that valvular calcification is a 
dominant finding after mediastinal radiotherapy for HL.80, 201 The present study suggests 
that this occurs late in the development of valvular pathology. Leaflet thickening and 
reduced movements without calcification were seen among those with no or only mild 
valvular stenosis/regurgitation. Valvular calcification was seen among those with 
moderate/severe valvular regurgitation/stenosis. CRP was elevated in our group of HLSs 
reflecting that a lasting inflammatory condition was initiated by radiotherapy. This was 
independent on whether the patients developed valvular dysfunction or not. The present 
study demonstrated no additional effect of anthracyclines on the development of valvular 
dysfunction while this has been reported by another study.57 Neither were we able to 
document an association between aortic stenosis and cholesterol.  
 
Figure 8 Possible connections between radiotherapy, cholesterol, atherosclerosis within 
the radiation field and peripheral endothelial dysfunction 
 
 
Radiotherapy Chemotherapy 
Endothelial 
dysfunction 
 Atherosclerosis 
Myocytes 
Ventricular  
remodelling 
Cholesterol 
PAS CACS CAD 
Valvular 
disease 
 64 
5 CONCLUSIONS 
Paper I 
Infra-diaphragmatic radiotherapy was associated with a low grade increase in markers of 
inflammation and endothelial dysfunction. Chemotherapy was associated with 
atherogenic lipid changes. 
 
Paper II 
TCSs with a CRP level ≥ 1.5 mg/L median 11 years after treatment had a more than twice 
as large risk for developing non-germ cell cancer and almost three times as high risk of 
CVD compared to survivors without elevated CRP levels during the eight consecutive 
years. Prior radiotherapy represented an added risk factor for cancer development.  
 
Paper III 
Hodgkin lymphoma survivors who were treated with mediastinal radiotherapy had a high 
risk of developing progressive valvular dysfunction and subsequent aortic stenosis during 
the second or third decade after treatment. Additional treatment with anthracyclines was 
associated with left ventricular remodeling.  
 
Paper IV 
There is a strong relationship between elevated coronary artery calcium score and clinical 
significant coronary artery disease in Hodgkin lymphoma survivors treated with 
mediastinal radiotherapy > 15 years earlier. 
 
Paper V 
In-field atherosclerotic lesions are frequent in Hodgkin lymphoma survivors treated with 
mediastinal radiotherapy. The atherosclerotic lesions in the coronary and pre-cranial 
arteries were predicted by elevated cholesterol and characterized by impaired peripheral 
endothelial function suggesting a target population that may benefit from statin treatment.  
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6 IMPLICATIONS FOR FOLLOW-UP AND FUTURE RESEARCH 
There are several similarities between TC and HL. The patients with TC and HL are 
typically young adults, the prognosis is excellent due to modern treatment with 
radiotherapy and multi-agent chemotherapeutic regimens and radiotherapy, and they are 
at risk of long-term adverse effects of the treatment. A diagnosis of cancer is always 
dramatic and has long-term psychological effects. Therefore it is important that the 
treatment is effective and has minimal acute and long-term side effects. The development 
and knowledge about anti-cancer drug treatment and their long-term adverse effects will 
allow us to develop strategies to minimize these effects and reduce the uncertainty among 
young cancer survivors. A thorough examination of TCSs and HLSs will allow us to 
reveal the presence of long-term adverse effects of the treatment where the most 
important concerns are the development of a second cancer and cardiovascular disease. 
The studies presented in Paper I – V demonstrate the presence and development of 
cardiovascular risk factors and disease in long-term cancer survivors. Based on the results 
from these studies we have some suggestions which are of relevance for health care and 
research.  
 
1) Primary prevention of CVD in TCSs and HLSs.  
It seems reasonable to recommend a regular follow-up of all TCSs and HLSs every 5 
years with the measurement of lipid-related markers and CRP (in TCSs) as well as 
assessment of other traditional risk factors like hypertension, smoking, waist 
circumference, physical activity and hypogonadism. Regarding HLSs treated with 
radiotherapy to the mediastinum or neck, the Norwegian Lymphoma group recommends 
regular examinations by the general practitioner from 10 years after treatment with the 
aim to prevent and early diagnose treatment-related cardiovascular adverse effects.  
 
- Further, studies should be undertaken to confirm if CRP is able to predict CVD 
and a second cancer in TCSs and examine if CRP may be of importance in larger 
cohorts of HLSs. Furthermore, there is a need to identify other predictive markers 
of a second cancer and CVD which can be of benefit in TCSs and HLSs.  
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- In HLSs especially the identification and treatment of high cholesterol may be of 
importance to prevent atherosclerosis and subsequent CVD. Though demanding 
from a practial point of view, our results warrant prospective studies to examine if 
treatment with statins before radiotherapy may prevent late adverse effects of 
radiation 
 
2) Reveal and treat premature CVD and a second cancer in TCSs and HLSs.  
- It is mandatory that these patients are referred to further examinations when they 
experience symptoms of CVD or a second cancer as these conditions may occur at a 
younger age than the general population.  
- The presence of a systolic or diastolic murmur in HLSs should call for an 
echocardiographic examination.   
- The clinical role of coronary calcification needs to be defined in a larger prospective 
study. This may be more important in this group than in the general population as arterial 
calcifications are prominent after mediastinal radiotherapy. The use of multi-detector CT 
may be useful as a screening procedure in the follow-up of HLSs in detecting premature 
subclinical cardiac disease. However; determination of CACS can not represent a “stand 
alone screening procedure” and the role of CACS in HLSs follow-up remains to be 
solved. 
 
3) Information to the patients, their family doctors and specialists in oncology and 
cardiovascular medicine. 
Knowledge about the increased incidence of CVD and second cancer in cancer survivors 
are necessary to elevate the awareness of these conditions. The Norwegian Health 
Directorate informed all Norwegian family doctors on the increased risk of CVD in 
irradiated HLSs. These initiatives were motivated partly by the findings in Paper III. 
However, also the patients have to be informed about symptoms of the adverse treatment 
related effects and their family doctors should have a low threshold for referring these 
patients to further examinations. Oncologists and cardiologists have to work in close 
cooperation to take care of these patients who often face multiple health problems like 
CVD, second cancer, infertility, hypothyreodism, muscular weakness etc. We have 
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recently constructed information leaflets for patients treated for lymphoma with 
mediastinal and or/neck radiotherapy to inform about their increased risk.  
 
Finally, it is important to keep in mind that even though these studies are performed in 
patients partly receiving “old-fashioned” treatment these patients will still be a part of the 
population for several decades. Furthermore, even modalities like involved-field 
radiotherapy to the mediastinum and/or the neck in HL patients may in many cases 
include the pre-cranial great arteries and the coronary arteries and these patients may also 
in the future be at increased risk. Thus, it is likely that today’s patient population with HL 
and TC cannot entirely avoid the risk of long-term treatment-related adverse effects. 
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ABSTRACT 
Purpose: C-reactive protein (CRP) is a marker of cardiovascular risk both in 
patients with cardiovascular disease (CVD) and in presumably healthy patients 
with normal LDL cholesterol while there is a conflicting evidence regarding CRP 
as a marker of future cancer. The aim was to assess whether CRP predicts CVD 
and consecutive cancer in testicular cancer survivors (TCSs).  
Methods: During 1998 – 2001, 586 TCSs with a high sensitivity CRP ≤ 10 mg/L 
were identified median 11 (4 – 21) years after treatment (FU-1). A second follow-
up survey (FU-2) was conducted median 8 (6 – 9) years after FU-1. At FU-2 we 
obtained information about post-FU-1 CVD (cardiovascular death, nonfatal 
myocardial infarction, stroke, revascularization or heart failure). Information about 
post-FU-1 non-germ cell cancer and cardiovascular death in all 622 patients 
were retrieved from the Cancer Registry of Norway. 
Results: After FU-1 31 (5.3%) of 586 patients developed non-germ cell cancer 
(excluding localized prostate cancer) while 28 (4.9%) developed CVD. Cox 
regression analyses showed that patients with CRP ≥ 1.5 mg/L had 2.21 (95% CI 
1.04 – 4.70) times higher risk of developing non germ cell cancer and 2.79 (95% 
CI 1.22 – 6.34) times higher risk for CVD compared to patients with a CRP < 1.5 
mg/L at FU-1. Radiotherapy was associated with 2.56 (95% CI 1.19 – 5.51) times 
higher risk for developing non-germ cell cancer in comparison to patients treated 
with surgery with or without chemotherapy. 
Conclusion: In long-term TCSs CRP may serve as a potential marker of 
cardiovascular events and a second cancer.  
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Introduction 
C-reactive protein (CRP) is established as a predictor of cardiovascular events in 
patients with known cardiovascular disease (CVD) as well as in asymptomatic 
individuals with risk factors for cardiovascular disease.1,2  CRP is an acute phase 
protein produced by the liver in response to inflammatory stimuli.3 Atherogenesis 
involves the tight interaction between lipids and inflammation and the ability of 
CRP to predict forthcoming cardiovascular events relies on its function as a 
stable and reliable marker of low-grade upstream inflammation. Chronic 
subclinical inflammation may also be associated with cancer for example as a 
pathogenic mediator in colon cancer, cervical cancer or gastric carcinoma.4 This 
hypothesis is supported by the observation of elevated CRP in patients with 
prevalent cancer as well as in patients who develop cancer several years after 
the registration of an elevated CRP.4-7 Recently, a CRP level ≥ 3 mg/l was 
identified as a marker of incident lung cancer in the general population in 
comparison to individuals with CRP < 1 mg/L.5 However, the association 
between CRP and cancer is still controversial. 7-9 
Long-term testicular cancer survivors (TCSs) treated with radiotherapy and/or 
chemotherapy have an increased risk of second malignancies and 
cardiovascular morbidity.10-13 Elevated levels of CRP and other markers of 
inflammation have been observed in TCSs several years after treatment with 
radiotherapy and chemotherapy.14,15 Thus, we have previously shown that TCSs 
treated with radiotherapy had elevated levels of CRP median 11 years after 
treatment compared with TCSs treated only with surgery or chemotherapy.15 
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However, it is still unknown whether elevated CRP levels seen in TCSs identify 
individuals at risk for developing a second cancer or CVD. The aim of this study 
was primarily to explore the hypothesis that elevated high sensitivity (hs) CRP 
levels determined at one occasion during long-term follow-up of TCSs may 
predict subsequent major cardiovascular events (i.e. cardiovascular death, 
nonfatal myocardial infarction, stroke, revascularization or heart failure) or non-
germ cell cancer in TCSs. Secondly, we wanted to study if treatment with 
radiotherapy shown to be associated with raised CRP levels was associated with 
an increased risk of CVD or a consecutive cancer.  
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Methods 
Patients 
Surviving TCSs treated for unilateral testicular cancer at the Norwegian Radium 
Hospital from1980 to1994 participated in a questionnaire-based survey 
conducted during 1998-2001 (FU-1).16 They also underwent an out-patient 
clinical examination at the hospital with determination of several biomarkers, 
among them CRP. Post-orchiectomy treatment consisted of retroperitoneal 
lymph node dissection alone or surveillance (n = 140), cisplatin-based 
chemotherapy with or without additional surgery (n = 240) or abdominal 
radiotherapy alone (n = 231, median dose 35 Gy). Only one patient received 
mediastinal radiotherapy. Twenty-eight patients received combined 
chemotherapy and radiotherapy. The chemotherapeutic agents used were 
cisplatin in the combination with bleomycin and vinblastin (before 1985) or 
etoposid (after 1985). Detailed treatment strategies of the surveyed men have 
been reported previously.15,16  At FU-1 patients were categorized as smokers 
versus never or previous smokers and as physically active or inactive..  
Eligibility criteria for the present study were aged  ≤ 60 years at FU-1, no known 
second cancer and no apparent acute or chronic infections at blood sampling 
thus excluding men with CRP > 10 mg/L and those in whom CRP was missing 
due to logistics reasons (Figure 1).  
A second questionnaire-based survey (FU-2) was conducted in 2007-2008 
median 8 (range 6 – 9) years after FU-1. Surviving TCSs were asked to have a 
clinical examination and blood sampling performed at their family doctor’s office. 
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The blood samples were immediately mailed to the NRH where all biochemical 
analyses were performed. At the time of FU-2, 19 men died; 4 died from CVD 
and 10 from cancer. The post-FU-1 development of a non-germ cell cancer or a 
first-time cardiovascular event represented the end-point of our analyses.  
 
Post-FU-1 non-germ cell cancer and CVD 
From the Norwegian Cancer Registry we received data (type of cancer, date of 
diagnosis) about non-germ cell cancer diagnosed after FU-1 among our eligible 
TCSs as registered by December 2008. The diagnosis of localized prostate 
cancer (n = 5) was not considered to be a valid event as this malignancy is 
increasingly detected by PSA screening. From the questionnaire at FU-2 we 
extracted information about first-time post-FU-1 cardiovascular events 
(myocardial infarction, stroke, revascularization, and hospitalization for heart 
failure) after exclusion of 15 men who had reported such an event prior to FU-1. 
All self-reported CV events were validated by the patient’s hospital medical 
record. The study was approved by Institutional and Regional Ethical 
Committees and funded by the University of Oslo. 
 
Biochemical analyses of serum and plasma 
At FU-1 non-fasting blood was sampled between 9 am and noon into pyrogen-
free, pre-cooled vials without additives (serum) or with EDTA as anticoagulant 
(plasma). The tubes were centrifuged at 1,000g for 10 minutes within 30 minutes 
(plasma) or allowed to clot before centrifugation (serum). All samples were stored 
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at -70°C and thawed < three times. High sensitivity CRP in plasma was 
determined by a high-sensitive particle-enhanced immunoturbidimetric assay 
(Roche Diagnostics, Basel Switzerland). Plasma levels of total cholesterol, low- 
and high density lipoprotein (LDL and HDL) cholesterol and triglycerides were 
measured enzymatically with a Roche/Hitachi 917 analyzer (Roche Diagnostics). 
Serum levels of luteinizing hormone (LH) and testosterone were analyzed by 
immunoassays.16 Patients were classified as having hypogonadism when any of 
the following 3 conditions were met: serum testosterone <8 nmol/L, serum LH 
>12 U/L, or regular use of exogenous testosterone.16 The intra- and inter-assay 
coefficients of variation were less than 10% for all assays.  
 
Statistical analyses 
Continuous variables were described with median (range or interquartile range; 
IQR) and categorical with proportions (percentages). Spearman’s correlation 
coefficient was computed to assess the correlation between hsCRP at FU-1 and 
-2. Mann-Whitney Wilcoxon and Kruskal-Wallis tests were used to compare 
continuous data with skewed distributions. Chi-square test or Fisher’s exact test 
were applied to compare categorical data. To determine the optimally 
discriminating CRP, we depicted the area under the curve (AUC) for the 
composite end- point of CV event and a second cancer and calculated that a cut 
point of CRP level at 1.5 mg/L reached sensitivity of 65% and  specificity of 58% 
(Online Figure 1). This cut-off level was used to construct groups of patients with 
CRP < 1.5 mg/L and ≥ 1.5 mg/L. The cumulative incidences of CVD and a 
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second cancer as separate end-points were computed for those two groups 
using Kaplan-Meier plots. The time to event was calculated from FU-1 to the date 
of the end-point, the date of FU-2 (for CVD events) or December 31, 2008 (for 
second cancer), whatever occurred first. Differences in time to event between 
groups were assessed using the log-rank test. Additional Kaplan-Meier plots 
were drawn to illustrate the impact of treatment modalities for which the log-rank 
test could not be performed. Therefore, to fulfil the proportional hazard 
assumption patients treated with only surgery and patients treated with 
chemotherapy were considered as one group in the Cox-regression models. 
Univariate and multiple Cox-regression models were fitted to explore the relation 
between clinically important predictors of second cancer or cardiovascular event. 
The limited number of events for each end-point allowed only three variables to 
be included in the multiple Cox regression model. Based on the univariate 
analyses and the main purpose of the study CRP, treatment (surgery ± 
chemotherapy versus radiotherapy ± chemotherapy) and age were entered into 
the multiple model. The categorical variables current smoking, physical active, 
education, hypogonadism and diabetes mellitus were not included in the 
analyses partly because there was no association between these variables and 
the end- points and additionally because they did not fulfil the proportional 
hazards assumption. There were significant correlations between systolic and 
diastolic blood pressure as well as between the total-, LDL- and HDL-cholesterol. 
To avoid multi colinearity, only systolic blood pressure and LDL-cholesterol were 
selected for the multiple Cox regression. A two-sided p-value <0.05 was 
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considered statistically significant. Data were analyzed using SPSS 14.0 (SPSS 
Inc). 
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Results 
Overall, 586 patients were included in FU-1 at a median of 11 (range 4 – 21) 
years after treatment. All were eligible for analyses of a second cancer while 571 
patients were eligible for analyses of CVD between FU-1 and FU-2. Patients who 
had been treated with radiotherapy (alone or with additional chemotherapy) were 
older both at diagnosis and at FU-1 and had a higher level of CRP at FU-1 
compared to the other two treatment groups (Table 1). There was a strong 
relationship between CRP-levels at FU-1 and FU-2 (Spearman r = 0.59, p < 
0.001). 
 
Non-germ cell cancer 
In total, 31 (5.3 %) of 586 patients developed non-germ cell cancer after FU-1, 
excluding 5 patients who were diagnosed with localized prostate cancer (Table 
2). Gastrointestinal cancer, kidney cancer, bladder cancer and skin cancer were 
the most frequent consecutive cancer types seen in TCSs. The cumulative 
incidence of non-germ cell cancer was significantly increased among TCSs with 
a CRP ≥ 1.5 mg/L as compared to those with CRP < 1.5 mg/L (Figure 2a; p = 
0.01). The multiple Cox regression analyses revealed that patients with a CRP 
level ≥ 1.5 mg/L at FU-1 had a 2.21 (95% CI 1.04 – 4.70) higher risk of 
developing non-germ cell cancer after adjustment for age and treatment (Table 
3). Systolic blood pressure was not associated with non-germ cell cancer after 
adjustment for age. Four patients developed non-germ cell cancer within 2 years 
after the measurement of CRP. The estimated risk of a second cancer was 2.16 
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(95% CI 0.97 – 4.82) after excluding these patients. Non-germ cell cancer and in 
particular gastrointestinal cancer were more prevalent and with a higher 
cumulative incidence in patients treated with radiotherapy as compared to 
patients treated with surgery only or chemotherapy (Figure 2c). Cox regression 
analyses demonstrated that patients treated with infra-diaphragmatic 
radiotherapy alone or in combination with chemotherapy had 2.56 (95% CI 1.19 – 
5.51) higher risk of developing a second cancer as compared to patients treated 
with surgery with or without chemotherapy (Table 3). Additionally, after the 
exclusion of the 22 patients who were registered to be treated with both 
radiotherapy and chemotherapy, treatment with only infra-diaphragmatic 
radiotherapy was associated with increased risk of a second cancer (HR 2.29 
(95% CI 1.03 – 5.07)).  
 
CVD 
Twenty-eight (4.9 %) TCSs were diagnosed with post-FU-1 cardiovascular event 
(Table 2). The most frequent CV events were myocardial infarction and 
revascularization. At FU-1 CRP was generally higher among patients who 
eventually developed CVD compared to those without events (median 1.9 (IQR 
1.2 – 3.6) mg/L vs median 1.2 (IQR 0.7 – 2.1) mg/L, p = 0.005). The positive 
predictive value of CRP ≥ 1.5 mg/L at FU-1 was only 10% while the 
corresponding negative predictive value was 97%. The cumulative incidence of 
CV events was increased among TCSs with a CRP ≥ 1.5 mg/L as compared to 
those with CRP < 1.5 mg/L (Figure 2b). Cox regression analyses demonstrated 
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that patients with a CRP ≥ 1.5 mg/L at FU-1 had 2.79 (95% CI 1.22 – 6.34) times 
higher risk of developing CV events after adjustment for age (Table 3). Systolic 
blood pressure and LDL-cholesterol were not associated with non-germ cell 
cancer after adjustment for age. The cumulative incidence of CVD was no 
different in the 3 treatment groups (Figure 2d). Cox-regression analyses did not 
reveal any influence of treatment modality on cardiovascular outcome.
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Discussion 
 
TCSs included in our study with a CRP level ≥ 1.5 mg/L had more than twice as 
large risk for developing non-germ cell cancer and almost three times as high risk 
of CVD compared to survivors without elevated CRP levels. Prior radiotherapy 
represented an additional risk factor for cancer development. On a group level 
the hsCRP obtained median 11 years after the testicular cancer diagnosis 
remained relatively stable for the consecutive 8 years, suggesting that this may 
represent an inflammatory phenotype of these patients.  
 
The increased risk of non-germ cell cancer and CVD in TCSs is documented with 
several studies.11-13,17,18 Radiotherapy has been shown to be the most important 
etiological factor for a second malignancy but it also contributes to CVD even if 
only administered infra-diaphragmatically.11,12 Second cancer is only partly 
explained by radiation-induced genetic mutations which lead to cancer by 
supplementary environmental influence. Long-term subclinical inflammation 
caused by infra-diaphragmatic radiotherapy in TCSs with release of cytokines 
may be of importance in mediating second cancer.15 The role of cisplatin-based 
chemotherapy in second solid cancer development is suggested but is less 
obvious; probably due to short observation times.18 On the other hand, cisplatin, 
which may be an etiological factor for both second cancer and CVD, can be 
demonstrated in serum or urine of TCSs more than 10 years after their 
chemotherapy.19,20 Oncologists have increasingly discussed the need of life-long 
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monitoring of TCSs, at least of high-risk TCSs. However, no biomarker is 
accepted for identification of TCSs at particular high risk of a second solid cancer 
or a CVD event. With this background we suggest that hsCRP might represent 
such a predictive factor. 
In patients with manifest cancer elevated CRP indicates a poor prognosis.21-23 
However, hsCRP may also predict a malignancy as cancer may etiologically be 
related to chronic infections by viral or bacterial agents (cervical cancer: human 
papilloma virus; gastric carcinoma: Helicobacter pylori).4-7. The majority of 
evidence is related to patients with colorectal cancer and lung cancer as 
demonstrated by recent studies and meta-analyses, although not all studies have 
supported this view.5-8  The results from the abovementioned studies may be 
confounded by patients who already had occult cancer at the time of CRP 
measurement or incidental elevation of CRP. Allin et al demonstrated that the 
association between CRP and cancer was attenuated after excluding patients 
diagnosed within 2 years after CRP measurement. In our study only 4 patients 
were diagnosed with non-germ cell cancer within 2 years from CRP 
measurement. After the exclusion of these patients, hsCRP ≥ 1.5 mg/L was still 
associated with future cancer, even though this association was attenuated, 
possibly due to the limited number of events among our TCSs. 
 
Cisplatin-based chemotherapy is today considered to be a possible factor in the 
development of premature atherosclerosis and CVD.11,12, 24 Hypertension, 
hypercholesterolemia and the metabolic syndrome are frequently observed 
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among TCSs and may contribute to the increased risk of CVD.24,25 Cisplatin-
based chemotherapy may lead to an increase in inflammatory markers and 
endothelial dysfunction as demonstrated by reduced flow-mediated dilatation and 
increased intima-media thickness.14,26 Large- field radiotherapy has similar 
effects predominantly on the vessels within the target field. 27 Previously we 
demonstrated elevated levels of hsCRP and von Willebrand factor in irradiated 
TCSs, most of them included in the present study.15 Other groups have observed 
similar alterations of inflammatory serum markers after chemotherapy.14,26 It is 
tempting to hypothesize that persistent subclinical endothelial inflammation after 
radiotherapy and/or chemotherapy, with on-going production of cytokines, may 
represent a common link between local or systemic cytotoxic treatment and the 
development of cardiovascular events in TCSs. Large studies with long follow-up 
have to confirm this hypothesis. 
After the demonstration that a hsCRP level above 2 mg/L identified individuals 
with increased risk of coronary heart disease, hsCRP has gained much interest 
as a potentially important tool in primary prevention of CVD.1,28 This is reflected 
in the recent JUPITER trial where cardiovascular morbidity and mortality were 
reduced by 44% in presumably healthy individuals with normal LDL-cholesterol 
but a CRP-level above 2 mg/L.2 There is an ongoing debate whether 
measurements of individual hsCRP values will give additional information beyond 
what is provided by the traditional risk scores. In the present study, a CRP level ≥ 
1.5 mg/L was better in predicting CVD than traditional risk factors. Recently, it 
has been demonstrated that biomarkers like CRP and N-BNP were not better 
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than traditional risk factors.29 In contrast; our study suggests that hsCRP may 
assist in identifying TCSs at increased risk of developing CVD. However, the 
positive predictive value was only 10% but the high negative predictive value of 
97% may indicate the usefulness as a first screening test to identify those with an 
elevated risk of CVD. If used together with other markers of future CVD it would 
be possible to compose test battery to identify individuals at risk of premature 
CVD who might benefit from primary prophylaxis with statins.  
The strength of our study is the prospective design, with the use of high 
sensitivity analyses of CRP applied for the first time in follow-up of TCSs. 
Furthermore, only 23 % were lost during follow-up, making selection bias 
unlikely. Previous studies and guidelines have demonstrated increased risk of 
CVD or cancer with the use of a cut-off at 1 mg/L, 2 mg/L or 3 mg/L which makes 
our cut-off at 1.5 mg/L reasonable.1, 2, 28  Nevertheless, some limitations have to 
be pointed out: The total number of our patients under observation and the 
number of TCSs who experienced an end-point was limited which gave some 
restrictions to our Cox regression analyses. The cardiovascular events in those 
alive are self-reported suggesting that the incidence of cardiovascular events 
might be underestimated, but all events reported by the patients were validated 
by medical records. We did not have an age-matched male control group 
available to investigate whether determination of elevated CRP is of greater 
value in TCSs than in the general population. We conclude that hsCRP might be 
a useful marker of cardiovascular events and non germ cell cancer among TCS 
irrespective of cancer treatment modality. Future large-scaled studies should 
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evaluate if CRP can be a useful marker in the screening of TCSs for the 
prevention of a second cancer and CVD.  
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 Table 1 Demographic and clinical characteristics among the 622 patients at FU-1 
(median 11 years after diagnosis) 
 
 Surgery only Chemotherapy Radiotherapy ± 
chemotherapy 
Number of patients (n=622) 132 221 233 
Age (years)1 
     at diagnose 
     at follow up 
 
29 (24 – 35) 
40 (36 – 47) 
 
28 (23 – 33) 
40 (34 – 45) 
 
34 (29 – 38) 
45 (40 – 51) 
Current smoker, n (%) 42 (32) 83 (38) 82 (35) 
Physical active, n (%) 107 (81) 186 (84) 191 (82) 
Education at university level, n (%) 44 (33) 90 (41) 94 (40) 
Gonadal function    
Hypogonadism, n (%)  7 (5) 31 (14) 21 (9) 
Lipid-related markers    
Total cholesterol (mmol/L) 5.6 (4.8 – 6.4) 5.6 (4.9 – 6.3) 5.6 (5.0 – 6.3) 
LDL cholesterol (mmol/L)  3.7 (3.1 – 4.3) 3.6 (3.0 – 4.2) 3.6 (3.1 – 4.2) 
HDL cholesterol (mmol/L)  1.2 (1.0 – 1.4) 1.1 (1.0 – 1.3) 1.1 (1.0 – 1.3) 
Triglycerides (mmol/L)  1.3 (0.9 – 2.0) 1.6 (1.0 – 2.5) 1.6 (1.0 – 2.4) 
Clinical markers    
Body mass index (kg/m2)  26.3 (24.4 – 28.6) 25.7 (23.7 – 27.9) 26.2 (24.1 – 28.4) 
Systolic blood pressure (mm Hg) 120 (115 – 130) 125 (120 – 140) 130 (120 – 140) 
Diastolic blood pressure (mm Hg) 80 (70 – 85) 80 (70 – 90) 80 (75 – 85) 
Diabetes mellitus I or II, n (%) 2 6 8 
Inflammatory marker    
hsCRP (mg/L)  1.2 (0.6 – 2.0) 1.2 (0.7 – 2.4) 1.5 (0.9 – 2.6) 
 
1Values are median (interquartile range) unless otherwise specified  
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Table 2 Clinical end points registered after FU-1 according to treatment  
 Surgery Chemotherapy Radiotherapy ± 
chemotherapy 
Total P-value 
 
A: Second cancer  
     
Eligible patients (FU-1) 132 221 233 586  
Gastrointestinal cancer 2 (1.5) 1 (0.5) 7 (3.0) 10 (1.7)  
Kidney - and bladder cancer 0 4 (1.8) 3 (1.3) 7 (1.2)  
Prostate cancer 1 (0.8) 1 (0.5) 4 (1.7) 6 (1.0)  
Melanoma  1 (0.8) 0 2 (0.9) 3 (0.5)  
Other* 0 2 (0.9) 8 (3.4) 10 (1.7)  
      
All second cancer 4 (3.0) 8 (3.6) 24 (10.3) 36 (6.1) 0.003 
All, except localized prostate 
cancer 
3 (2.3) 7 (3.2) 21 (9.0) 31 (5.3) 0.004 
 
B: Cardiovascular events** 
     
Eligible patients (FU-2) 130 216 225 571  
Nonfatal myocardial infarction 2 (1.5) 5 (2.3) 6 (2.6) 13 (2.3)  
Nonfatal stroke 2 (1.5) 2 (0.9) 2 (0.9) 6 (1.1)  
Revascularization 3 (2.3) 6 (2.8) 6 (2.6) 15 (2.6)  
Heart failure 0 2 (0.9) 1 (0.4) 3 (0.5)  
Death from cardiovascular 
disease 
0 1 (0.5) 3 (1.3)  4 (0.7)  
      
Any 5 (3.8) 10 (4.6) 13 (5.8) 28 (4.9) 0.70 
 
* Pulmonary cancer (1), brain cancer (1), peripheral nerve system, pelvis (1), 
pancreatic cancer (1), laryngeal cancer (2), cancer in the lymphatic system (1), 
peritoneal cancer (1), squamous cell carcinoma (2) 
** Fifteen patients with CVD before FU-1 were excluded. Cardiovascular events 
registered after FU-1 included death due to CVD, nonfatal myocardial infarction, 
nonfatal stroke, coronary revascularization and heart failure.  
Data are numbers (%) 
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Figure 1 Flow-diagram of the recruited patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invited to FU-1 
968 
Excluded1 
109 
Non-eligible  
Eligible2 
859 
Non-responders in FU-13 
220 (26%) 
Obs.time4:             14 (6-20) 
Age at follow-up: 43 (24-60) 
Surgery:       42 (19%) 
Radiotherapy:     73 (33%) 
Chemotherapy:   92 (42%) 
Radio- and Chemotherapy: 13 (6%) 
Responders in FU-1; 639 (74%)  
Responders in FU-2 
430 (76%) 
Non-responders in FU-23 
137 (24%)  
Obs.time4:             18 (13-28) 
Age at follow-up4: 47 (32-67) 
Surgery:         26 (19%) 
Radiotherapy:       48 (35%) 
Chemotherapy:     59(43%) 
Radio- and Chemotherapy: 4 (3%) 
Obs.time4:            20 (13-28) 
Age at follow-up4: 51 (31-69) 
Surgery:         105 (24%) 
Radiotherapy:        152 (35%) 
Chemotherapy:      158 (37%) 
Radio- and Chemotherapy: 15 (4%) 
Deaths after FU-1: 19 (3%) 
- CVD: 4  
- Cancer: 10  
- Other: 5  
Invited to FU-2 
567 
Obs.time4:             11 (4-21) 
Age at follow-up: 42 (23-60) 
Surgery:       132 (23%) 
Radiotherapy:      211 (36%) 
Chemotherapy:    221 (38%) 
Radio- and Chemotherapy: 22 (4%) 
CRP at FU-1 ≤ 10 mg/L; 586 (68%) 
 31 
Abbreviations: FU-1: first follow-up survey; FU-2: second follow-up survey; CVD: 
cardiovascular disease 
1Age at survey >60 years; 2Invited patients eligible for FU-1; 3Without out-patient 
visit, questionnaire or lack of blood sampling; 4 p:<0.01, all other comparisons 
p:>0.05; Observation time and age at follow-up are presented as median and 
range. Other values are number (%). 
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Figure 2 Cumulative Incidence of non-germ cell cancer (Panel A) and 
cardiovascular disease (Panel B) according to CRP-level ≥ or below 1.5 mg/L. 
Cumulative Incidence of non germ cell cancer (Panel C) and CVD (Panel D) 
according to treatment group 
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Panel D 
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 Online Figure 1 Area under the curve for CRP and second cancer or 
cardiovascular disease. CRP ≥ 1.5 mg/L had a sensitivity of 65% and specificity 
at 58% to predict cardiovascular disease or second cancer. Area under the 
curve: 0.58 (95% CI 0.51 – 0.66), p = 0.04). 
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